US20080311613A1 - Artificial skin surface film liquids - Google Patents
Artificial skin surface film liquids Download PDFInfo
- Publication number
- US20080311613A1 US20080311613A1 US12/137,391 US13739108A US2008311613A1 US 20080311613 A1 US20080311613 A1 US 20080311613A1 US 13739108 A US13739108 A US 13739108A US 2008311613 A1 US2008311613 A1 US 2008311613A1
- Authority
- US
- United States
- Prior art keywords
- acid
- sebum
- composition
- artificial
- sweat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 196
- 210000004243 sweat Anatomy 0.000 claims abstract description 185
- 210000002374 sebum Anatomy 0.000 claims abstract description 155
- 238000009472 formulation Methods 0.000 claims abstract description 98
- 239000000470 constituent Substances 0.000 claims abstract description 88
- 239000000126 substance Substances 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000000243 solution Substances 0.000 claims description 69
- 238000004090 dissolution Methods 0.000 claims description 55
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 54
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 51
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 50
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 49
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 48
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
- 229910001868 water Inorganic materials 0.000 claims description 44
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 40
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 38
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 36
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 35
- 229940024606 amino acid Drugs 0.000 claims description 35
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 34
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 34
- 229940088594 vitamin Drugs 0.000 claims description 34
- 229930003231 vitamin Natural products 0.000 claims description 34
- 235000013343 vitamin Nutrition 0.000 claims description 34
- 239000011782 vitamin Substances 0.000 claims description 34
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 33
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 33
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 33
- 239000003792 electrolyte Substances 0.000 claims description 33
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 30
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 30
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 30
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 29
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 28
- 239000011575 calcium Substances 0.000 claims description 28
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 26
- 235000019192 riboflavin Nutrition 0.000 claims description 26
- 229960002477 riboflavin Drugs 0.000 claims description 26
- 239000002151 riboflavin Substances 0.000 claims description 26
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 25
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 25
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 25
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 25
- 229940031439 squalene Drugs 0.000 claims description 25
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 25
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 24
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 claims description 24
- 239000004164 Wax ester Substances 0.000 claims description 24
- 235000012000 cholesterol Nutrition 0.000 claims description 24
- 235000020960 dehydroascorbic acid Nutrition 0.000 claims description 24
- 239000011615 dehydroascorbic acid Substances 0.000 claims description 24
- 229940093915 gynecological organic acid Drugs 0.000 claims description 24
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 24
- 150000007524 organic acids Chemical class 0.000 claims description 24
- 235000005985 organic acids Nutrition 0.000 claims description 24
- 150000003626 triacylglycerols Chemical class 0.000 claims description 24
- 235000019386 wax ester Nutrition 0.000 claims description 24
- 150000001840 cholesterol esters Chemical class 0.000 claims description 23
- 229910052742 iron Inorganic materials 0.000 claims description 23
- 239000011133 lead Substances 0.000 claims description 23
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 22
- 229960005069 calcium Drugs 0.000 claims description 22
- 229910052791 calcium Inorganic materials 0.000 claims description 22
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 22
- 235000021588 free fatty acids Nutrition 0.000 claims description 22
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 22
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 22
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 21
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 21
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 21
- 235000010323 ascorbic acid Nutrition 0.000 claims description 21
- 239000011668 ascorbic acid Substances 0.000 claims description 21
- 229960005070 ascorbic acid Drugs 0.000 claims description 21
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 20
- 229930003427 Vitamin E Natural products 0.000 claims description 20
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 20
- 239000011709 vitamin E Substances 0.000 claims description 20
- 229940046009 vitamin E Drugs 0.000 claims description 20
- 235000019165 vitamin E Nutrition 0.000 claims description 20
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 19
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 19
- 229940077731 carbohydrate nutrients Drugs 0.000 claims description 19
- 150000001720 carbohydrates Chemical class 0.000 claims description 19
- 235000014633 carbohydrates Nutrition 0.000 claims description 19
- 239000004310 lactic acid Substances 0.000 claims description 19
- 235000014655 lactic acid Nutrition 0.000 claims description 19
- 235000001968 nicotinic acid Nutrition 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 18
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 18
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 18
- 229960000304 folic acid Drugs 0.000 claims description 18
- 235000019152 folic acid Nutrition 0.000 claims description 18
- 239000011724 folic acid Substances 0.000 claims description 18
- 229960003512 nicotinic acid Drugs 0.000 claims description 18
- 239000011664 nicotinic acid Substances 0.000 claims description 18
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims description 18
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 18
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 claims description 17
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 17
- 239000004471 Glycine Substances 0.000 claims description 17
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 17
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 17
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 17
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 17
- 239000004202 carbamide Substances 0.000 claims description 17
- 229940109239 creatinine Drugs 0.000 claims description 17
- 229960002449 glycine Drugs 0.000 claims description 17
- 229960002885 histidine Drugs 0.000 claims description 17
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 17
- 229960000367 inositol Drugs 0.000 claims description 17
- 229960003136 leucine Drugs 0.000 claims description 17
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 17
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 17
- 229960004295 valine Drugs 0.000 claims description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 239000004473 Threonine Substances 0.000 claims description 16
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 claims description 16
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 16
- 229960000310 isoleucine Drugs 0.000 claims description 16
- 239000012088 reference solution Substances 0.000 claims description 16
- 229960002898 threonine Drugs 0.000 claims description 16
- 229960004441 tyrosine Drugs 0.000 claims description 16
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 15
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 15
- 235000019161 pantothenic acid Nutrition 0.000 claims description 15
- 229960005190 phenylalanine Drugs 0.000 claims description 15
- 235000019260 propionic acid Nutrition 0.000 claims description 15
- 229940107700 pyruvic acid Drugs 0.000 claims description 15
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 15
- 239000011701 zinc Substances 0.000 claims description 15
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 14
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 14
- 239000010949 copper Substances 0.000 claims description 14
- 229940055726 pantothenic acid Drugs 0.000 claims description 14
- 239000011713 pantothenic acid Substances 0.000 claims description 14
- 229940116269 uric acid Drugs 0.000 claims description 14
- 229910019142 PO4 Inorganic materials 0.000 claims description 13
- 229910052759 nickel Inorganic materials 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000004475 Arginine Substances 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 12
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 12
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 12
- 229960003767 alanine Drugs 0.000 claims description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- 229960003121 arginine Drugs 0.000 claims description 12
- 235000009697 arginine Nutrition 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 229960001031 glucose Drugs 0.000 claims description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 12
- 229960003646 lysine Drugs 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- 239000011593 sulfur Substances 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 239000004474 valine Substances 0.000 claims description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- 239000004472 Lysine Substances 0.000 claims description 11
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 11
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 11
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 11
- 235000004279 alanine Nutrition 0.000 claims description 11
- 229960005261 aspartic acid Drugs 0.000 claims description 11
- 235000003704 aspartic acid Nutrition 0.000 claims description 11
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 11
- 229960001231 choline Drugs 0.000 claims description 11
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 11
- 229960002173 citrulline Drugs 0.000 claims description 11
- 235000013477 citrulline Nutrition 0.000 claims description 11
- 229960003624 creatine Drugs 0.000 claims description 11
- 239000006046 creatine Substances 0.000 claims description 11
- 229960002989 glutamic acid Drugs 0.000 claims description 11
- 235000013922 glutamic acid Nutrition 0.000 claims description 11
- 239000004220 glutamic acid Substances 0.000 claims description 11
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 11
- 229960003104 ornithine Drugs 0.000 claims description 11
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 11
- 235000008160 pyridoxine Nutrition 0.000 claims description 11
- 239000011677 pyridoxine Substances 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 229940083542 sodium Drugs 0.000 claims description 11
- 229960003495 thiamine Drugs 0.000 claims description 11
- 235000019157 thiamine Nutrition 0.000 claims description 11
- 239000011721 thiamine Substances 0.000 claims description 11
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 11
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 claims description 11
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 11
- 229940011671 vitamin b6 Drugs 0.000 claims description 11
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 claims description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 10
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 claims description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 10
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 10
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 9
- 235000021355 Stearic acid Nutrition 0.000 claims description 9
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 claims description 9
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 9
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 claims description 9
- 230000003647 oxidation Effects 0.000 claims description 9
- 238000007254 oxidation reaction Methods 0.000 claims description 9
- 239000011591 potassium Substances 0.000 claims description 9
- 229910052700 potassium Inorganic materials 0.000 claims description 9
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 9
- 229940117972 triolein Drugs 0.000 claims description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 8
- FEYJIFXFOHFGCC-UHFFFAOYSA-N 1-nitrohexane Chemical compound CCCCCC[N+]([O-])=O FEYJIFXFOHFGCC-UHFFFAOYSA-N 0.000 claims description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 8
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-fructopyranose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 claims description 8
- 239000005642 Oleic acid Substances 0.000 claims description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- MPTQRFCYZCXJFQ-UHFFFAOYSA-L copper(II) chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Cu+2] MPTQRFCYZCXJFQ-UHFFFAOYSA-L 0.000 claims description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- 235000019743 Choline chloride Nutrition 0.000 claims description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- 235000021314 Palmitic acid Nutrition 0.000 claims description 7
- 239000000908 ammonium hydroxide Substances 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 7
- 229960003178 choline chloride Drugs 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 7
- 239000011572 manganese Substances 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- 229910052793 cadmium Inorganic materials 0.000 claims description 6
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004826 creatine monohydrate Drugs 0.000 claims description 6
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 229940091250 magnesium supplement Drugs 0.000 claims description 6
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 6
- 235000011164 potassium chloride Nutrition 0.000 claims description 6
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 6
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 6
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 6
- 235000011152 sodium sulphate Nutrition 0.000 claims description 6
- CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 5
- 239000002211 L-ascorbic acid Substances 0.000 claims description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 5
- 229930182844 L-isoleucine Natural products 0.000 claims description 5
- 239000004395 L-leucine Substances 0.000 claims description 5
- 235000019454 L-leucine Nutrition 0.000 claims description 5
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 claims description 5
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 5
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims description 5
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 5
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 claims description 5
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 claims description 5
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 claims description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 5
- 239000001488 sodium phosphate Substances 0.000 claims description 5
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 5
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 5
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 claims description 4
- NLQMSBJFLQPLIJ-UHFFFAOYSA-N (3-methyloxetan-3-yl)methanol Chemical compound OCC1(C)COC1 NLQMSBJFLQPLIJ-UHFFFAOYSA-N 0.000 claims description 4
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 4
- 239000007832 Na2SO4 Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229950010030 dl-alanine Drugs 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- OHZZTXYKLXZFSZ-UHFFFAOYSA-I manganese(3+) 5,10,15-tris(1-methylpyridin-1-ium-4-yl)-20-(1-methylpyridin-4-ylidene)porphyrin-22-ide pentachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].C1=CN(C)C=CC1=C1C(C=C2)=NC2=C(C=2C=C[N+](C)=CC=2)C([N-]2)=CC=C2C(C=2C=C[N+](C)=CC=2)=C(C=C2)N=C2C(C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 OHZZTXYKLXZFSZ-UHFFFAOYSA-I 0.000 claims description 4
- YDWPOGYTJVQQIL-UHFFFAOYSA-N methyl 2-(4-aminophenoxy)acetate Chemical compound COC(=O)COC1=CC=C(N)C=C1 YDWPOGYTJVQQIL-UHFFFAOYSA-N 0.000 claims description 4
- 235000021313 oleic acid Nutrition 0.000 claims description 4
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims description 4
- 229960003975 potassium Drugs 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 229910021592 Copper(II) chloride Inorganic materials 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 238000010998 test method Methods 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 150000002889 oleic acids Chemical class 0.000 claims description 2
- 150000002943 palmitic acids Chemical class 0.000 claims description 2
- FOFYPMPFTYORPL-UHFFFAOYSA-N azanium;2,8-dioxo-7,9-dihydro-3h-purin-6-olate Chemical compound N.N1C(=O)NC(=O)C2=C1NC(=O)N2 FOFYPMPFTYORPL-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 230000031018 biological processes and functions Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 47
- 238000012360 testing method Methods 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 13
- 229910017052 cobalt Inorganic materials 0.000 description 12
- 239000010941 cobalt Substances 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 229910052721 tungsten Inorganic materials 0.000 description 12
- 239000010937 tungsten Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000003278 mimic effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000009506 drug dissolution testing Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 6
- 206010012442 Dermatitis contact Diseases 0.000 description 6
- 208000010247 contact dermatitis Diseases 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 238000000638 solvent extraction Methods 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- -1 theroinine Chemical compound 0.000 description 6
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000007922 dissolution test Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 210000004378 sebocyte Anatomy 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000005388 borosilicate glass Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 229950001574 riboflavin phosphate Drugs 0.000 description 2
- 150000003287 riboflavins Chemical class 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 210000000106 sweat gland Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940045136 urea Drugs 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
- NDFCCFWNBAZVMD-UHFFFAOYSA-N 2-amino-3-methyl-4h-imidazol-5-one;hydrate Chemical compound O.CN1CC(=O)N=C1N NDFCCFWNBAZVMD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004228 Riboflavin-5'-Phosphate Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940032362 superoxide dismutase Drugs 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- MYVIATVLJGTBFV-UHFFFAOYSA-M thiamine(1+) chloride Chemical compound [Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N MYVIATVLJGTBFV-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- UDKYUQZDRMRDOR-UHFFFAOYSA-N tungsten Chemical compound [W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W][W] UDKYUQZDRMRDOR-UHFFFAOYSA-N 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N17/00—Investigating resistance of materials to the weather, to corrosion, or to light
- G01N17/006—Investigating resistance of materials to the weather, to corrosion, or to light of metals
Definitions
- Sebum is secreted by pilosebaceous units, which are sebaceous glands physically connected via a sebaceous duct to a hair follicle. Sebaceous glands are present in all areas of the skin except for the palms of the hands and soles of the feet. Undifferentiated sebocyte cells, located at the periphery of a sebaceous gland, are pushed through a maturation zone in the gland, where they are filled with a freshly synthesized lipid mixture to develop into differentiated sebocyte cells. These cells then pass through a zone of necrosis in the gland where they increase 100- to 150-fold in volume by accumulating more lipids to form mature sebocyte cells. This lipid accumulation causes the mature sebocyte cells to disintegrate and release sebum into the sebaceous duct. Sebum is then secreted via hair follicles onto the surface of the skin where it mixes with epidermally derived lipids.
- Another artificial sweat formulation is defined by the European Committee for Standardization (CEN) in EN 1811 as a simple solution of 0.5% NaCl, 0.1% urea and 0.1% lactic acid, with a pH adjusted to 6.5 using NH 4 OH.
- the ISO standard ISO 3160-2 includes 20 g/L NaCl, 17.5 g/L NH 4 OH, 5 g/L acetic acid and 15 g/L d,l-lactic acid with the pH adjusted to 4.7 by NaOH.
- the amount of dissolution from a test article in an individual constituent of artificial SSFL can be less than the amount of dissolution in the SSFL mixture (Collins, Br. J. Industrial Med. 14(3): 191-197, 1957; Hemingway and Molokhia, Contact Dermatitis 16: 99-105, 1987; Stauber et al., The Science of the Total Environment 74: 235-247, 1994).
- the electrolytes include sodium, chloride, calcium, potassium, magnesium, phosphate and bicarbonate;
- the ionic constituents include sulfate, sulfur, fluoride, phosphorous, bromine, cadmium, copper, iodide, iron, lead, manganese, nickel, zinc;
- the organic acids include lactic acid, pyruvic acid, butyric acid, acetic acid, hexanoic acid, propionic acid, isobutyric acid, and isovaleric acid;
- the carbohydrates include glucose;
- the amino acids include alanine, arginine, aspartic acid, citrulline, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, ornithine, phenylalanine, threonine, tyrosine, and valine;
- the nitrogenous substances include ammonium, uric acid, creatinine and creatine; and the vitamins include thiamine, ribof
- Methods of making an artificial sweat composition are also disclosed, in which a volume of water of about 70-80% of a final desired liquid volume of the artificial sweat composition are provided.
- the primary electrolytes and ionic constituents are added to the water to form a primary solution, then the organic acids, amino acids, nitrogenous substances and vitamins are added to the primary solution.
- Solubility of vitamins in the artificial sweat is enhanced at a pH greater than 4.8, for example a pH of 4.8-5.8, for example 5.0-5.5 or 5.3.
- Methods are also disclosed for preserving the separately stored sebum formulation by refrigerating it in a container under a nitrogen gas blanket, for example at less than 10° C., such as at 4° C.
- the amino acids are present in the L-form, for example as L-Alanine (C 3 H 7 NO 2 ), L-(+)-Arginine (C 6 H 14 N 4 O 2 ), L-(+)-Aspartic acid (C 4 H 7 NO 4 ), L-(+)-Citrulline (C 6 H 13 N 3 O 3 ), L-(+)-Glutamic acid (C 5 H 9 NO 4 ), Glycine (C 2 H 5 NO 2 ), L-Histidine (C 6 H 9 N 3 O 2 ), L-Isoleucine (C 6 H 13 NO 2 ), L-Leucine (C 6 H 13 NO 2 ), L-(+)-Lysine (for example in the form of L-Lysine-Monohydrochloride (C 6 H 14 N 2 O 2 .HCl)), L-(+)-Ornithine (for example as L-Ornithine Monohydrochloride (C 5 H 12 N 2 O 2 .HCl)
- the composition including artificial SSFL or sweat/sebum alone is present at a volume so that the test article is completely immersed within the composition (such as at a ratio of 1 mL artificial SSFL per cm 2 of test article surface area).
- a volume can be used that exposes either one or both the internal and external surfaces to the composition.
- the duration of the in vitro dissolution studies can vary.
- an in vitro dissolution test is of sufficient length for the amount of material that dissolves to exceed the applicable analytical method reporting limit.
- the duration can range from a few minutes to several days, such as from about one hour to about 120 days.
- the duration of the dissolution is dependent upon whether the dissolution is mono-phasic (linear with time), biphasic (rapid initial phase followed by slower long-term phase), or multi-phasic (rapid initial phase, slower long-term phase, and a third very long-term phase).
- time required for biphasic or multi-phase dissolution can be several weeks to months, depending on the characteristics of the test article.
- the disclosed artificial SSFL represents a comprehensive artificial sweat solution which includes 60 constituents identified in human sweat, as well as a representative sebum component. Of the 60 constituents, all but riboflavin were present in concentrations that corresponded to median values reported in human sweat. Despite containing 60 different constituents, including antioxidants such as ascorbic acid (vitamin C), this comprehensive artificial formulation (like all artificial formulations) lacks enzymatic free radical scavengers present in dynamic biological systems, e.g., Cu/Zn-super oxide dismutase and Mn-superoxide dismutase (Richelle et al., Br. J. Nutr. 96: 227-238, 2006).
- This example provides a method of preparing a comprehensive artificial sweat formulation.
- Vitamin constituents were added to the solution last (see Table 2).
- Dehydroascorbic acid was prepared by oxidizing an equal molar concentration of ascorbic acid (described in Example 2 below).
- dehydroascorbic acid calibration standards six 100 mL solutions of ascorbic acid were prepared at concentrations that ranged from 1 ⁇ 10 ⁇ 2 M through 1 ⁇ 10 ⁇ 7 M, using decade dilutions.
- the ascorbic acid solutions were completely oxidized to dehydroascorbic acid by adding 200 ⁇ L of the enzyme ascorbate oxidase to each solution, then incubating at 37° C. for 30 minutes.
- a spectrophotometer Spectronic 20 Genesys, Spectronic Instruments, Inc., Rochester, N.Y.
- the pH of human sweat ranges from 2.1 to 8.2, with a median value of 5.3, but varies due to endogenous (e.g., age, ethnicity, sebum content, sweat content) and exogenous (e.g., use of cosmetics, soaps, occlusive dressings) factors.
- the formulation of comprehensive sweat described herein has a pH that mimics the median value of human sweat; however, this formulation may not be suitable for analyzing the behavior of materials in artificial SSFL under more acidic conditions. If the pH of this artificial sweat formulation was below 4.8, precipitation of salts occurred rapidly.
- This example provides a detailed protocol for preparing artificial sweat.
- the artificial sweat formulation was prepared by providing 80% of the desired final volume of 18M ⁇ distilled and deionized water to a large carboy (4.8 L water for 6 L batch or 7.2 L water for 9 L batches). A stir bar and temperature probe were placed in the container then stirring begun at 450 rpm on a magnetic stir plate while warming to 36.3° C. (Model 11-800-495SHP, Fisher Scientific, Dubuque, Iowa). The inlet side of an in-line HEPA filter (HEPA-CAP 36, Whatman Inc., Florham Park, N.J.) was connected to an air supply and an aeration stone was connected to the outlet side of the filter. An aeration stone was placed in the water of the carboy and air bubbled into the liquid for 1 hour to saturate it with air.
- HEPA filter HEPA-CAP 36, Whatman Inc., Florham Park, N.J.
- a weighing dish was placed on a calibrated microbalance (Model XS205, Mettler-Toledo, Gaccosee, Switzerland). Each constituent (beginning with sodium sulfate) was weighed out or pipeted in the appropriate mass or volume of each constituent, and the weighed mass of the constituent recorded. The weighed mass was then transferred to the appropriate carboy then the weighing dish rinsed with water to ensure complete transfer into beaker. Each of the constituents was transferred in this manner, in the order in listed in Table 4 below.
- Sodium Iodide Dissolve 0.010 g NaI in 0.050 L water
- Sodium Fluoride Dissolve 0.020 g NaF in 0.050 L water
- Sodium Bromide Dissolve 0.010 g NaBr in 0.050 L water
- Cadmium Chloride Anhydrous Dissolve 0.010 g CdCl 2 in 0.050 L water
- Copper Chloride Dihydrate Dissolve 0.010 g CuCl 2 .2H 2 O in 0.050 L water
- Lead Reference Solution Pipet 1.0 mL lead reference solution in 0.050 L water g.
- Additional filter sandwiches were made without powder at a ratio of 1 in 10 for use as blanks.
- One undosed sandwich was placed into a static dissolution chamber then stored in a clean, re-sealable plastic bag.
- Bulk tungsten, tungsten carbide, or cobalt powder was used to spike filter sandwiches containing known amount of particles (using the same masses as experimental samples) at a ratio of 1 in 10 per material type.
- Solvent was removed from the remaining tubes by evaporation under nitrogen and the tubes with lipids split into two sets, one was maintained at 4° C. to characterize storage and the other at 32° C. to characterize use conditions (e.g., mimic human skin conditions). For each set, triplicate samples were harvested for analysis at 2, 4, 7, 9, 11, 14, 16, 18, 21, 23, 25, and 28 days.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Ecology (AREA)
- Environmental & Geological Engineering (AREA)
- Environmental Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
An artificial skin surface film liquid (SSFL) is disclosed that mimics the chemical composition and biological action of both human sweat and sebum. The artificial sweat formulation contains a comprehensive combination of constituents. When combined with the sebum component it is particularly effective at modeling the effect of the skin surface film liquid on agents in contact with the skin. Also provided are methods of making and using the disclosed artificial skin surface compositions.
Description
- This application claims the benefit of priority under 35 U.S.C. §119 to U.S. Provisional Application No. 60/934,861 filed on Jun. 14, 2007, which is incorporated herein by reference in its entirety
- The present disclosure relates to artificial skin surface compositions that mimic the properties of human sweat and sebum on the skin and methods of making and using compositions thereof.
- The skin is the largest human organ, and its interaction with the environment has many important health consequences. For example, chemicals may be unintentionally leached from jewelry, textiles or cosmetics to cause contact dermatitis, skin irritation or toxicity. Drugs that are applied in topical compositions to the skin can interact with the skin surface in a way that affects the bioavailability of the active pharmaceutical agent. The skin surface film liquid (SSFL) is a significant factor that affects the interaction of the skin with such agents.
- Sweat is secreted by sweat glands, which are tubular structures having a coil portion and a duct portion. The coil portion is located in the dermis of the skin and secretes a precursor sweat solution. The duct portion in the epidermis of the skin modifies the precursor sweat solution by reabsorbing ionic constituents (mostly sodium and chloride) before the solution reaches the skin surface where it is secreted as sweat. Sweat on the skin surface is the modified product of an active secretory function of epithelial cells that line the coiled portion of the sweat gland and constituents formed as by-products of the skin surface maturation and desquamation processes and metabolism by skin bacteria.
- Sebum is secreted by pilosebaceous units, which are sebaceous glands physically connected via a sebaceous duct to a hair follicle. Sebaceous glands are present in all areas of the skin except for the palms of the hands and soles of the feet. Undifferentiated sebocyte cells, located at the periphery of a sebaceous gland, are pushed through a maturation zone in the gland, where they are filled with a freshly synthesized lipid mixture to develop into differentiated sebocyte cells. These cells then pass through a zone of necrosis in the gland where they increase 100- to 150-fold in volume by accumulating more lipids to form mature sebocyte cells. This lipid accumulation causes the mature sebocyte cells to disintegrate and release sebum into the sebaceous duct. Sebum is then secreted via hair follicles onto the surface of the skin where it mixes with epidermally derived lipids.
- Human SSFL is a mixture of approximately 50% sweat and 50% sebum. The composition of an artificial SSFL is important for accurate in vitro modeling of potential chemical release on human skin. To provide meaningful results about potential chemical release and percutaneous absorption of agents in contact with the skin, a comprehensive artificial SSFL is needed that accurately mimics human SSFL. Unfortunately, a comprehensive understanding of the chemical composition of SSFL has not previously been available.
- Prior SSFLs have primarily attempted to mimic the chemical content of sweat by including in it such components as sodium, chloride, potassium, lactic acid, amino acids and urea. One particularly comprehensive synthetic sweat composition was disclosed by Boman et al. (Contact Dermatitis 9: 159-160, 1983) which incorporated 14 constituents of sweat maintained at a pH of 5.1. This composition included Na+, Cl−, OH−, K2SO4, KCl, Ca(H2PO4)2.H2O, urea, arginine, histidine, valine, leucine, threonine, glucose, NH3 and lactic acid.
- Another artificial sweat formulation, the most commonly used today, is defined by the European Committee for Standardization (CEN) in EN 1811 as a simple solution of 0.5% NaCl, 0.1% urea and 0.1% lactic acid, with a pH adjusted to 6.5 using NH4OH. The ISO standard ISO 3160-2 includes 20 g/L NaCl, 17.5 g/L NH4OH, 5 g/L acetic acid and 15 g/L d,l-lactic acid with the pH adjusted to 4.7 by NaOH.
- One of the more comprehensive summaries of the composition of eccrine sweat and the aqueous film surface was provided in Rothman et al., Physiology and Biochemistry of the Skin, University of Chicago Press (1954), chapter 7. This reference noted that eccrine sweat contains nitrogenous compounds, glucose, lactic acid, water-soluble vitamins and electrolytes. However, even this detailed treatment failed to disclose a composition that closely mimicked the complex content of SSFL.
- The chemical composition of an artificial SSFL is important for accurate in vitro modeling of potential dissolution on human skin. For example, gold readily dissolves in artificial SSFL that contains certain sulfur-containing amino acids (Brown et al., Inorganica Chimica Acta 67: 27-30, 1982; Rapson, Gold Bull 15: 19-20, 1982; and Rapson, Contact Dermatitis 13: 56-65, 1985), but not in artificial SSFL that lacks these constituents (Lidén et al., Contact Dermatitis 39: 281-285, 1998a). Copper dissolution decreases as the sodium chloride concentration of artificial SSFL increases (Boman et al., Contact Dermatitis 9: 159-160, 1983). Additionally, the amount of dissolution from a test article in an individual constituent of artificial SSFL can be less than the amount of dissolution in the SSFL mixture (Collins, Br. J. Industrial Med. 14(3): 191-197, 1957; Hemingway and Molokhia, Contact Dermatitis 16: 99-105, 1987; Stauber et al., The Science of the Total Environment 74: 235-247, 1994).
- The role of individual artificial SSFL constituents in the dissolution of metals, coupled with the observation that dissolution levels in individual constituents can differ from that of the mixture, highlight the need for a comprehensive artificial SSFL and in vitro test system that accurately match SSFL in vivo. A better understanding of material bioavailability will also improve the quality of data available for risk decision making to protect even the most susceptible persons from adverse health effects due to chemicals that leach from articles in contact with the skin.
- The inventors have found that prior sweat formulations are unable to mimic the chemical complexity of SSFL, and therefore are unable to accurately model the interaction of environmental agents (such as consumer products and drugs) with the skin. For example, the inventors identified and critically reviewed 45 prior formulations of artificial sweat and 18 formulations of artificial sebum (in studies published from 1940 through 2005). This review determined that human sweat has a median pH of 5.3 and contains at least 60 different chemical constituents (see Table 1). Among the 45 formulations of artificial sweat, most lacked many of the constituents in human sweat. Additionally, concentrations of constituents in these artificial sweat formulations were often not within ranges found in human sweat.
- Disclosed herein are artificial SSFL compositions that mimic the properties of human sweat and sebum on the skin. In some disclosed embodiments, the artificial SSFL composition includes an artificial sweat composition that includes electrolytes, ionic constituents, organic acids, carbohydrates, nitrogenous substances and vitamins in concentrations found in human sweat, and maintained at a pH of 4.8-5.8, for example 5.0-5.5.
- In a particular example, the electrolytes include sodium, chloride, calcium, potassium, magnesium, phosphate and bicarbonate; the ionic constituents include sulfate, sulfur, fluoride, phosphorous, bromine, cadmium, copper, iodide, iron, lead, manganese, nickel, zinc; the organic acids include lactic acid, pyruvic acid, butyric acid, acetic acid, hexanoic acid, propionic acid, isobutyric acid, and isovaleric acid; the carbohydrates include glucose; the amino acids include alanine, arginine, aspartic acid, citrulline, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, ornithine, phenylalanine, threonine, tyrosine, and valine; the nitrogenous substances include ammonium, uric acid, creatinine and creatine; and the vitamins include thiamine, riboflavin, nicotinic acid, pantothenic acid, pyridoxine, folic acid, ascorbic acid, dehydroascorbic acid, inositol, choline and p-aminobenzoic acid, and the artificial sweat composition is maintained at a pH of 5.1-5.5.
- In a more particular example, the electrolytes are present in a molar concentration of Na (3.0-3.5×10−2), Cl (2.0-2.5×10−2), Ca (5.0-5.5×10−3), K (5.8-6.2×10−3), Mg (1.0-1.5×10−4), PO4 (2.8-3.4×10−4), and HCO3 (2.7-3.3×10−3); the ionic constituents are present in a concentration of SO4 (3.9-4.5×10−4), S (2.0-2.6×10−3), F (0.8-1.4×10−5), P (1.0-1.6×10−5), Br (2.0-2.6×10−6), Cd (1.5-2.1×10−8), Cu (9.1-9.7×10−7), I (6.8-7.4×10−8), Fe (9.5-10.1×10−6), Pb (0.9-1.5×10−7), Mn (0.8-1.4×10−6), Ni (3.9-4.5×10−7), and Zn (1.0-1.6×10−5); the organic acids and carbohydrates are present in concentrations of lactic acid (1.1-1.7×10−2), pyruvic acid (1.5-2.1×10−4), butyric acid (2.1-2.7×10−6), acetic acid (1.0-1.6×10−4), hexanoic acid (8.7-9.3×10−7), propionic acid (3.2-3.8×10−6), isobutyric acid (7.7-8.3×10−7), isovaleric acid (0.8-1.4×10−6), and glucose (1.4-2.0×10−4); the amino acids are present in concentrations of alanine (3.3-3.9×10−4), arginine (7.5-8.1×10−4), aspartic acid (3.1-3.7×10−4), citrulline (3.7-4.3×10−4), glutamic acid (3.4-4.0×10−4), glycine (3.6-4.2×10−4), histidine (4.9-5.5×10−4), isoleucine (1.4-2.0×10−4), leucine (1.8-2.4×10−4), lysine (1.2-1.8×10−4), ornithine (1.2-1.8×10−4), phenylalanine (1.0-1.6×10−4), threonine (4.2-4.8×10−4), tryptophan (5.2-5.8×10−5), tyrosine (1.4-2.0×10−4), and valine (2.2-2.8×10−4); the nitrogenous substances are present in a concentration of NH3 (4.9-5.5×10−3), urea (0.7-1.3×10−2), uric acid (5.6-6.2×10−5), creatinine (8.1-8.7×10−5), and creatine (1.2-1.8×10−5); the vitamins are present in a concentration of thiamine (4.7-5.3×10−3), riboflavin (1.7-2.5×10−3), niacin (3.8-4.4×10−1), pantothenic acid (1.0-1.6×10−1), pyridoxine (0.7-1.3×10−8), folic acid (1.3-1.9×10−8), ascorbic acid (0.7-1.3×10−5) and/or its oxidation product dehydroascorbic acid (0.8-1.4×10−5), inositol (1.3-1.9×10−6), choline (2.3-2.9×10−5), and p-aminobenzoic acid (6.8-7.4×10−8).
- In an even more particular example, artificial SSFL constituent concentrations match those of human sweat. The electrolytes are present in molar concentrations of Na (3.1×10−2), Cl (2.3×10−2), Ca (5.2×10−3), K (6.1×10−3), Mg (8.2×10−5), PO4 (3.1×10−4), and HCO3 (3×10−3); ionic constituents are present in a concentration of SO4 (4.2×10−4), S (2.3×10−3), F (1.1×10−5), P (1.3×10−5), Br (2.3×10−6), Cd (1.8×10−8), Cu (9.4×10−7), I (7.1×10−8), Fe (9.8×10−6), Pb (1.2×10−7), Mn (1.1×10−6), Ni (4.2×10−7), and Zn (1.3×10−5); organic acids and carbohydrates are present in concentrations of lactic acid (1.4×10−2), pyruvic acid (1.8×10−4), butyric acid (2.4×10−6), acetic acid (1.3×10−4), hexanoic acid (9.0×10−7), propionic acid (3.5×10−6), isobutyric acid (8.0×10−7), isovaleric acid (1.1×10−6), and glucose (1.7×10−4); amino acids are present in concentrations of alanine (3.6×10−4), arginine (7.8×10−4), aspartic acid (3.4×10−4), citrulline (4.0×10−4), glutamic acid (3.7×10−4), glycine (3.9×10−4), histidine (5.2×10−4), isoleucine (1.7×10−4), leucine (2.1×10−4), lysine (1.5×10−4), ornithine (1.5×10−4), phenylalanine (1.3×10−4), threonine (4.5×10−4), tryptophan (5.5×10−5), tyrosine (1.7×10−4), and valine (2.5×10−4); the nitrogenous substances are present in concentrations of NH3 (5.2×10−3), urea (1.0×10−2), uric acid (5.9×10−5), creatinine (8.4×10−5), and creatine (1.5×10−5); the vitamins are present in concentrations of thiamine (5.0×10−3), riboflavin (2.0×10−3), niacin (4.1×10−1), pantothenic acid (1.3×10−1), pyridoxine (1.0×10−8), folic acid (1.6×10−8), ascorbic acid (1.0×10−5) and/or its oxidation product dehydroascorbic acid (1.1×10−5), inositol (1.6×10−6), choline (2.6×10−5), and p-aminobenzoic acid (7.1×10−8); and the composition is at a pH of about 5.3.
- The composition can, in some examples, further include a sebum formulation that includes squalene, wax esters, triglycerides, free fatty acids, cholesterol esters, free cholesterol and vitamin E in concentrations found in human sebum. For example, the sebum formulation may include 8-12% squalene, 23-27% wax esters, 30-35% triglycerides, 25-30% free fatty acids, 1-3% cholesterol esters, and 3-5% free cholesterol, and in more particular examples 10% squalene, 25% wax esters, 33% triglycerides, 28% free fatty acids, 2% cholesterol esters, and 4% free cholesterol. The wax esters may include palmityl palmitate and oleyl oleate; the triglycerides include tristearin and triolein; the free fatty acids include stearic, palmitic and oleic acid; the cholesterol esters include cholesteryl oleate; and the Vitamin E is (±)-α-tocopherol.
- More detailed formulations of artificial sweat and sebum formulations are described below, such as in the Example Section. The artificial sweat and sebum formulations may be prepared and stored separately, and combined at the time of dissolution testing. Methods are also disclosed for performing dissolution testing using the artificial sweat and sebum formulations. Although dissolution testing in the combined sweat and sebum formulations provide particularly good results, testing can also be performed separately with the sweat and sebum formulations to determine how these subcomponents of SSFL interact with particular test objects. Test methods include testing dissolution of an object (such as a metal, cloth or pharmaceutical object) in human sweat by exposing the object to the composition for a sufficient period of time for it to at least partially dissolve, then quantifying dissolution of the object in the composition. The comprehensive artificial sweat and sebum formulations disclosed herein have been found to provide greater and more accurate dissolution of objects than has been obtained with prior formulations.
- Methods of making an artificial sweat composition are also disclosed, in which a volume of water of about 70-80% of a final desired liquid volume of the artificial sweat composition are provided. The primary electrolytes and ionic constituents are added to the water to form a primary solution, then the organic acids, amino acids, nitrogenous substances and vitamins are added to the primary solution. Solubility of vitamins in the artificial sweat is enhanced at a pH greater than 4.8, for example a pH of 4.8-5.8, for example 5.0-5.5 or 5.3. Methods are also disclosed for preserving the separately stored sebum formulation by refrigerating it in a container under a nitrogen gas blanket, for example at less than 10° C., such as at 4° C.
- The foregoing and other features of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
-
FIG. 1 is a bar graph illustrating similar dissolution rates of cobalt by three disclosed artificial SSFL formulations. -
FIG. 2 is a bar graph illustrating enhanced dissolution of tungsten powder and cobalt powder by a disclosed artificial SSFL formulation as compared to a CEN 1811 sweat formulation. Dissolution rates of the poorly soluble tungsten carbide material were not observed to be influenced by solvent pH or composition. - Ca+2=calcium
CE=cholesterol esters
CH=cholesterol
Cl−=chloride
Co=cobalt
CISA=chloride ionic strength adjuster (for use with chloride ion selective electrode)
° C.=degrees centigrade
FA=fatty acids
Fe+2=iron
g=gram (1 g=1000 mg)
ICV=initial calibration verification sample
ISA=ionic strength adjuster (for use with calcium ion selective electrode)
ISE=ion selective electrode
L=liter (1 L=1000 mL)
M=molar
Mω==megohm
mg=milligram
mL=milliliter
mm=millimeter
mV=millivolt
μm=micrometer
N2 gas=nitrogen gas - ppm=parts per million (1 ppm=1 mg/L)
SQ=squalene
SRM®=standard reference material
TG=triglycerides
W=tungsten
WC=tungsten carbide
WE=wax esters - “Amino acids” are acids that include an amino group, a carboxyl group, a hydrogen atom, and a distinctive R group bonded to a carbon atom. Some (but not all) amino acids are the structural units of proteins. The twenty amino acids encoded by the genetic code are called “standard amino acids.” These amino acids have the structure H2N—CHR—COOH, where R is a side chain specific to the amino acids. Standard amino acids are alanine, arginine, aspargine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, theroinine, tryptophan, tyrosine, and valine. The amino acids citrulline and ornithine are non-standard amino acids that are not encoded by DNA and are not involved in protein synthesis, but are an intermediate in metabolic processes. In humans, the amino acids are present in the L-form, for example as L-Alanine (C3H7NO2), L-(+)-Arginine (C6H14N4O2), L-(+)-Aspartic acid (C4H7NO4), L-(+)-Citrulline (C6H13N3O3), L-(+)-Glutamic acid (C5H9NO4), Glycine (C2H5NO2), L-Histidine (C6H9N3O2), L-Isoleucine (C6H13NO2), L-Leucine (C6H13NO2), L-(+)-Lysine (for example in the form of L-Lysine-Monohydrochloride (C6H14N2O2.HCl)), L-(+)-Ornithine (for example as L-Ornithine Monohydrochloride (C5H12N2O2.HCl)), L-Phenylalanine (C9H11NO2), L-Threonine (C4H9NO3), L-(−)-Tryptophan (C11H12N2O2), L-Tyro sine (C9H11NO3), and L-Valine (C5H11NO2).
- “Electrolytes” are ionized salts (ionic constituents) in body fluids that are generally capable of conducting an electrical current. The major electrolytic constituents in body fluids are made from sodium, potassium, magnesium, calcium, chloride, bicarbonate, and phosphate. Examples of electrolyte and ionic substances that may be dissolved in artificial human sweat include Sodium Sulfate (Na2SO4), Sodium Iodide (NaI), Sodium Fluoride (NaF), Sodium Bromide (NaBr), Cadmium Chloride Anhydrous (CdCl2), Copper (II) Chloride Dihydrate (CuCl2.2H2O), Ammonium Hydroxide (NH4OH), Sulfur (S), Iron Sulfate Heptahydrate (FeSO4.7H2O), Lead (Pb), Manganese (II), Chloride (MnCl2), Nickel (Ni), Zinc (Zn), Sodium Bicarbonate (NaHCO3), Potassium Chloride (KCl), Magnesium Chloride Hexahydrate (MgCl2.6H2O), Sodium Phosphate Anhydrous Monobasic (NaH2PO4), Calcium Chloride Dihydrate (CaCl2.2H2O), Phosphorous Pentachloride (PCl5), and Sodium Chloride (NaCl).
- A “nitrogenous substance” is a compound that contains a nitrogen, for example a nitrogen base. Examples of nitrogenous substances that may be found in human sweat include ammonium, uric acid (C5H4N4O3), urea (CH4N2O), creatinine (C4H7N3O), and creatine (for example as creatine monohydrate (C4H9N3O2.H2O)).
- “Organic acid” is an acid made up of organic radicals, and which contains the ionizable COOH group. Examples of organic acids that may be found in human sweat include lactic acid (CH3CH(OH)COONa), pyruvic acid (C3H4O3), butyric acid (C4H8O2), acetic acid (C2H4O2), hexanoic acid (C6H12O2), propionic acid (C3H6O2), isobutyric acid (C4H8O2), isovaleric acid (C5H10O2), and D(+)-glucose (C6H12O6).
- “Vitamins” are essential low molecular weight organic compounds that are required in trace amounts for normal growth and metabolic processes; they often serve as components of coenzyme systems. Examples of vitamins that may be found in human sweat include thiamine (for example as thiamine hydrochloride (C12H17ClN4OS.HCl)), riboflavin (C17H20N4O6), nicotinic acid (C6H5NO2), pantothenic acid (for example as D-Pantothenic Acid (C9H17NO5)), pyridoxine (for example as pyridoxine hydrochloride (C8H11NO3.HCl)), folic acid (C19H19N7O6), ascorbic acid (for example as L-(+)-ascorbic acid (C6H8O6) and/or dehydroascorbic acid), inositol (C6H12O6), choline (for example as choline chloride (C5H14NOCl)), and aminobenzoic acid (for example as p-Aminobenzoic Acid (C7H7NO2)).
- The term “human sweat” is defined as non-exercise-induced eccrine (thermoregulatory) sweat secreted by healthy adult humans.
- “Skin Surface Film Liquid” or “SSFL” encompasses historically used terms such as “artificial sweat,” “acidic artificial sweat,” “artificial perspiration,” “synthetic perspiration,” “synthetic sweat,” “sweat simulant,” and “simulated sweat.” The artificial SSFL disclosed herein contains both artificial sweat and artificial sebum components, which is contrary to the common understanding of prior SSFL compositions.
- Human sweat is composed of highly variable amounts of primary electrolytes, ionic constituents, organic acids and carbohydrates, amino acids, nitrogenous substances, and vitamins and other miscellaneous constituents (Table 1). Sweat is 99.0 to 99.5% water and 0.5 to 1.0% solids (about half inorganic and half organic), with a specific gravity of 1.001 to 1.008. The composition of sweat can vary among people, and is also affected by age, diet, season, degree of acclimation, activity level, gender and race. The inventors therefore determined the range of components of sweat, and in disclosed embodiments provided a sweat formulation substantially having a mean concentration of most of the components of sweat for inclusion in a SSFL that would more closely mimic the formulation of the native liquid and its effect on items placed on the skin. This composition provides a superior dissolution medium for SSFL testing. The constituents of human sweat, and their median concentrations, are shown in Table 1.
-
TABLE 1 Median values of human sweat constituents Constituents Concentration (M) Primary electrolytes Sodium 3.1 × 10−2 Chloride 2.3 × 10−2 Calcium 5.2 × 10−3 Potassium 6.1 × 10−3 Magnesium 8.2 × 10−5 Phosphate 3.1 × 10−4 Bicarbonate 3.0 × 10−3 Ionic constituents Sulfate 4.2 × 10−4 Sulfur 2.3 × 10−3 Fluoride 1.1 × 10−5 Phosphorous 1.3 × 10−5 Bromine 2.3 × 10−6 Cadmium 1.8 × 10−8 Copper 9.4 × 10−7 Iodide 7.1 × 10−8 Iron 9.8 × 10−6 Lead 1.2 × 10−7 Manganese 1.1 × 10−6 Nickel 4.2 × 10−7 Zinc 1.3 × 10−5 Organic acids and carbohydrates Lactic acid 1.4 × 10−2 Pyruvic acid 1.8 × 10−4 Butyric acid 2.4 × 10−6 Acetic acid 1.3 × 10−4 Hexanoic acid 9.0 × 10−7 Propionic acid 3.5 × 10−6 Isobutyric acid 8.0 × 10−7 Isovaleric acid 1.1 × 10−6 Glucose 1.7 × 10−4 Amino acids Alanine 3.6 × 10−4 Arginine 7.8 × 10−4 Aspartic acid 3.4 × 10−4 Citrulline 4.0 × 10−4 Glutamic acid 3.7 × 10−4 Glycine 3.9 × 10−4 Histidine 5.2 × 10−4 Isoleucine 1.7 × 10−4 Leucine 2.1 × 10−4 Lysine 1.5 × 10−4 Ornithine 1.5 × 10−4 Phenylalanine 1.3 × 10−4 Threonine 4.5 × 10−4 Tryptophan 5.5 × 10−5 Tyrosine 1.7 × 10−4 Valine 2.5 × 10−4 Nitrogenous Substances Ammonium 5.2 × 10−3 Uric acid 5.9 × 10−5 Urea 1.0 × 10−2 Creatinine 8.4 × 10−5 Creatine 1.5 × 10−5 Vitamins Thiamine 5.0 × 10−3 Riboflavin 2.0 × 10−2 Nicotinic Acid 4.1 × 10−1 Pantothenic Acid 1.3 × 10−1 Pyridoxine 1.0 × 10−8 Folic Acid 1.6 × 10−8 Ascorbic Acid 1.0 × 10−5 Dehydroascorbic Acid 1.1 × 10−5 Inositol 1.6 × 10−6 Choline 2.6 × 10−5 p-Aminobenzoic Acid 7.1 × 10−8 - The artificial SSFL compositions disclosed herein include both artificial sweat and artificial sebum. The artificial sweat formulations disclosed herein have one or more constituents (for example at least five or more constituents) from at least each of the categories of primary electrolytes, ionic constituents, organic acids and carbohydrates, and amino acids, for example at about the median concentrations shown in Table 1. In other embodiments, the artificial sweat formulation has all but five, three or one of the constituents in Table 1, and the constituents are present in about the median concentrations shown in that Table. In some embodiments the artificial sweat contains all of the listed constituents in substantially the median concentrations shown.
- The artificial SSFL composition can, in some examples, further include a sebum formulation that includes squalene, wax esters, triglycerides, free fatty acids, cholesterol esters, free cholesterol and vitamin E in concentrations found in human sebum. For example, the sebum formulation may include 8-12% squalene, 23-27% wax esters, 30-35% triglycerides, 25-30% free fatty acids, 1-3% cholesterol esters, and 3-5% free cholesterol, and in more particular examples 10% squalene, 25% wax esters, 33% triglycerides, 28% free fatty acids, 2% cholesterol esters, and 4% free cholesterol. The wax esters may include palmityl palmitate and oleyl oleate; the triglycerides include tristearin and triolein; the free fatty acids include stearic, palmitic and oleic acid; the cholesterol esters include cholesteryl oleate; and the Vitamin E is (±)-α-tocopherol.
- Methods of making an artificial sweat composition are also disclosed, in which a volume of water of about 70-80% of a final desired liquid volume of the artificial sweat composition is provided. The primary electrolytes and ionic constituents are added to the water to form a primary solution, then the organic acids, amino acids, nitrogenous substances and vitamins are added to the primary solution.
- In one disclosed embodiment, artificial sweat is prepared by combining the 60 constituents in the following five general classifications: primary electrolytes and other ionic constituents, organic acids and carbohydrates, amino acids, nitrogenous substances, and vitamins. For example, primary electrolytes (bicarbonate, sodium, calcium, chloride, manganese, phosphate, and potassium) and ionic constituents can be added first. Following addition of the electrolytes and ionic constituents, ionic concentrations can be measured, such as by using calcium and chloride ion selective electrodes. For example, the concentration of iron, calcium or chloride can be measured using semi-quantitative calorimetric test strips to determine if the measured values match that predicted from the weighed masses of the respective compounds. Organic acids (primarily in liquid form), followed by amino acids, nitrogenous substances, and vitamins can then be added to the solution. The artificial sweat composition can be maintained at a pH of 4.8-6.5, for example 5.0-5.5. In some examples, the sweat composition is stored at temperatures close to body temperature, for example 35-38° C., such as 36-37° C., to prevent or reduce precipitation and/or recrystallization of the constituents.
- In a particular example, the electrolytes in the artificial sweat composition include sodium, chloride, calcium, potassium, magnesium, phosphate and bicarbonate; the ionic constituents include sulfate, sulfur, fluoride, phosphorous, bromine, cadmium, copper, iodide, iron, lead, manganese, nickel, zinc; the organic acids include lactic acid, pyruvic acid, butyric acid, acetic acid, hexanoic acid, propionic acid, isobutyric acid, and isovaleric acid; the carbohydrates include glucose; the amino acids include alanine, arginine, aspartic acid, citrulline, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, ornithine, phenylalanine, threonine, tyrosine, and valine; the nitrogenous substances include ammonium, uric acid, creatinine and creatine; and the vitamins include thiamine, riboflavin, nicotinic acid, pantothenic acid, pyridoxine, folic acid, ascorbic acid, dehydroascorbic acid, inositol, choline and p-aminobenzoic acid, and the artificial sweat composition is maintained at a pH of 5.1-5.5.
- In a more particular example, the electrolytes in the artificial sweat composition are present in a molar concentration of Na (3.0-3.5×10−2), Cl (2.0-2.5×10−2), Ca (5.0-5.5×10−3), K (5.8-6.2×10−3), Mg (1.0-1.5×10−4), PO4 (2.8-3.4×10−4), and HCO3 (2.7-3.3×10−3); the ionic constituents are present in a concentration of SO4 (3.9-4.5×10−4), S (2.0-2.6×10−3), F (0.8-1.4×10−5), P (1.0-1.6×10−5), Br (2.0-2.6×10−6), Cd (1.5-2.1×10−8), Cu (9.1-9.7×10−7), I (6.8-7.4×10−8), Fe (9.5-10.1×10−6), Pb (0.9-1.5×10−7), Mn (0.8-1.4×10−6), Ni (3.9-4.5×10−7), and Zn (1.0-1.6×10−5); the organic acids and carbohydrates are present in concentrations of lactic acid (1.1-1.7×10−2), pyruvic acid (1.5-2.1×10−4), butyric acid (2.1-2.7×10−6), acetic acid (1.0-1.6×10−4), hexanoic acid (8.7-9.3×10−7), propionic acid (3.2-3.8×10−6), isobutyric acid (7.7-8.3×10−7), isovaleric acid (0.8-1.4×10−6), and glucose (1.4-2.0×10−4); the amino acids are present in concentrations of alanine (3.3-3.9×10−4), arginine (7.5-8.1×10−4), aspartic acid (3.1-3.7×10−4), citrulline (3.7-4.3×10−4), glutamic acid (3.4-4.0×10−4), glycine (3.6-4.2×10−4), histidine (4.9-5.5×10−4), isoleucine (1.4-2.0×10−4), leucine (1.8-2.4×10−4), lysine (1.2-1.8×10−4), ornithine (1.2-1.8×10−4), phenylalanine (1.0-1.6×10−4), threonine (4.2-4.8×10−4), tryptophan (5.2-5.8×10−5), tyrosine (1.4-2.0×10−4), and valine (2.2-2.8×10−4); the nitrogenous substances are present in a concentration of NH3 (4.9-5.5×10−3), urea (0.7-1.3×10−2), uric acid (5.6-6.2×10−5), creatinine (8.1-8.7×10−5), and creatine (1.2-1.8×10−5); the vitamins are present in a concentration of thiamine (4.7-5.3×10−3), riboflavin (1.7-2.5×10−3), niacin (3.8-4.4×10−1), pantothenic acid (1.0-1.6×10−1), pyridoxine (0.7-1.3×10−8), folic acid (1.3-1.9×10−8), ascorbic acid (0.7-1.3×10−5) and/or its oxidation product dehydroascorbic acid (0.8-1.4×10−5), inositol (1.3-1.9×10−6), choline (2.3-2.9×10−5), and p-aminobenzoic acid (6.8-7.4×10−8).
- In an even more particular example, artificial SSFL constituent concentrations match those of human sweat. The electrolytes are present in the artificial sweat composition in molar concentrations of Na (3.1×10−2), Cl (2.3×10−2), Ca (5.2×10−3), K (6.1×10−3), Mg (8.2×10−5), PO4 (3.1×10−4), and HCO3 (3×10−3); ionic constituents are present in a concentration of SO4 (4.2×10−4), S (2.3×10−3), F (1.1×10−5), P (1.3×10−5), Br (2.3×10−6), Cd (1.8×10−8), Cu (9.4×10−7), I (7.1×10−8), Fe (9.8×10−6), Pb (1.2×10−7), Mn (1.1×10−6), Ni (4.2×10−7), and Zn (1.3×10−5); organic acids and carbohydrates are present in concentrations of lactic acid (1.4×10−2), pyruvic acid (1.8×10−4), butyric acid (2.4×10−6), acetic acid (1.3×10−4), hexanoic acid (9.0×10−7), propionic acid (3.5×10−6), isobutyric acid (8.0×10−7), isovaleric acid (1.1×10−6), and glucose (1.7×10−4); amino acids are present in concentrations of alanine (3.6×10−4), arginine (7.8×10−4), aspartic acid (3.4×10−4), citrulline (4.0×10−4), glutamic acid (3.7×10−4), glycine (3.9×10−4), histidine (5.2×10−4), isoleucine (1.7×10−4), leucine (2.1×10−4), lysine (1.5×10−4), ornithine (1.5×10−4), phenylalanine (1.3×10−4), threonine (4.5×10−4), tryptophan (5.5×10−5), tyrosine (1.7×10−4), and valine (2.5×10−4); the nitrogenous substances are present in concentrations of NH3 (5.2×10−3), urea (1.0×10−2), uric acid (5.9×10−5), creatinine (8.4×10−5), and creatine (1.5×10−5); the vitamins are present in concentrations of thiamine (5.0×10−3), riboflavin (2.0×10−3), niacin (4.1×10−1), pantothenic acid (1.3×10−1), pyridoxine (1.0×10−8), folic acid (1.6×10−8), ascorbic acid (1.0×10−5) and/or its oxidation product dehydroascorbic acid (1.1×10−5), inositol (1.6×10−6), choline (2.6×10−5), and p-aminobenzoic acid (7.1×10−8); and the composition is at a pH of about 5.3.
- Methods of making artificial sebum formulations are also disclosed herein. In some examples, sebum constituents are dissolved in a 2:1 co-solvent (chloroform:methanol). For example, sebum constituents including squalene, wax esters, triglycerides, free fatty acids, cholesterol esters, free cholesterol and vitamin E in concentrations as found in human sebum are dissolved in the 2:1 chloroform:methanol co-solvent solution.
- In some examples, the sebum formulation include 8-12% squalene, 23-27% wax esters, 30-35% triglycerides, 25-30% free fatty acids, 1-3% cholesterol esters, and 3-5% free cholesterol, and in more particular examples 10% squalene, 25% wax esters, 33% triglycerides, 28% free fatty acids, 2% cholesterol esters, and 4% free cholesterol. The wax esters can also include palmityl palmitate and oleyl oleate; the triglycerides include tristearin and triolein; the free fatty acids include stearic, palmitic and oleic acid; the cholesterol esters include cholesteryl oleate; and the Vitamin E is (±)-α-tocopherol. In one example, the artificial sebum formulation is prepared to include at least 10% by mass of squalene; at least 20% wax esters; triglycerides; at least 25% free fatty acids; at least 1% cholesterol esters; at least 2% free cholesterol; and Vitamin E. In other embodiments, the sebum preparation includes about 10% squalene; 25% wax esters; 28% free fatty acids; 2% cholesterol esters; 4% free cholesterol; with the balance being triglycerides with a trace amount of Vitamin E.
- In some examples, the prepared stock sebum solution can be stored at ambient atmosphere or under a nitrogen gas blanket and maintained at either room temperature (e.g., 23° C.) or at reduced temperature, such as less than 10° C. In a particular example, the stock sebum solution is maintained at 4° C. and under a nitrogen gas blanket. The artificial sweat and sebum formulations may be prepared and stored separately, and combined at the time of use, such as at the time of dissolution testing.
- It is contemplated that additional methods known to one of skill in the art can be used to prepare the disclosed artificial sebum formulations, such as other solvent formulations (e.g., 3:1 chloroform:methanol) or microemulsion (e.g., Komesvarakul et al., J. Cosmet. Sci. 55: 309-325, 2006).
- The exact mechanism by which sweat and sebum combine to form SSFL on human skin is not fully known, however several approaches can be used to formulate the disclosed artificial SSFL that contains both the artificial sweat and sebum. In some examples, artificial SSFL can be prepared by adding 500 mL of a disclosed artificial sweat composition at 35° C. to a molten mixture of a disclosed artificial sebum composition and stirring the two compositions, such as with a powerful whisk. In other examples, artificial SSFL can be prepared by emulsification.
- Another approach to combining the artificial sweat and sebum is provided in the dissolution tests described in Example 9, in which a filter is coated with sebum and immersed in the artificial sweat to simulate SSFL on the surface of the skin. The sebum/sweat ratio can be varied to generate a sebum layer thickness ranging from approximately 0.05 to approximately 4 μm. In certain embodiments, the sebum is present on a mass basis in a ratio of at least or no more than 0/100, 1/99, 5/95, 10/90, 30/70, 50/50, 70/30, 90/10, 95/5, or 99/1. In one particular example, a mass basis of less than 1% sebum to 99% sweat can be used to generate a sebum layer thickness of approximately 2±1 μm
- Methods are disclosed for performing dissolution testing using the artificial sweat and sebum formulations either in combination (e.g., as artificial SSFL) or alone. Although dissolution testing in the combined sweat and sebum formulations provide particularly good results (as described below), testing can be performed separately with the sweat and sebum formulations to determine how these subcomponents of SSFL interact with particular test objects. Exemplary test methods include testing dissolution of an object (such as a metal, cloth or pharmaceutical object) in human sweat by exposing the object to the composition, including one of the disclosed sweat and/or sebum formulations, for a sufficient period of time for the composition to at least partially dissolve, then quantifying dissolution of the object in the composition.
- A variety of in vitro test systems are available for assessing dissolution, including a static system and its variations (CEN, 1998; ISO, 2003), flow-through systems, and electrochemical systems. In some examples, a validated standard analytical method is employed with known reporting limits to minimize error associated with quantifying the mass of analyte that dissolves from a test article into the composition. For example, a limit of detection (LOD), defined as the mass of analyte that gives a mean signal three standard deviations above the mean blank signal, and/or a limit of quantification (LOQ), defined as the mass of analyte that gives a signal ten standard deviations above the mean blank signal, can be used. In certain examples, the composition including artificial SSFL or sweat/sebum alone is present at a volume so that the test article is completely immersed within the composition (such as at a ratio of 1 mL artificial SSFL per cm2 of test article surface area). For test articles and materials with biologically relevant internal and external surface areas, a volume can be used that exposes either one or both the internal and external surfaces to the composition.
- The duration of the in vitro dissolution studies can vary. In one example, an in vitro dissolution test is of sufficient length for the amount of material that dissolves to exceed the applicable analytical method reporting limit. For example, the duration can range from a few minutes to several days, such as from about one hour to about 120 days. In some examples, the duration of the dissolution is dependent upon whether the dissolution is mono-phasic (linear with time), biphasic (rapid initial phase followed by slower long-term phase), or multi-phasic (rapid initial phase, slower long-term phase, and a third very long-term phase). For example, time required for biphasic or multi-phase dissolution can be several weeks to months, depending on the characteristics of the test article.
- The temperature of in vitro dissolution studies can also vary for the temperature of the composition can influence dissolution. For example, the temperature of the compositions can range from 10° C. to 100° C. In particular examples, the composition temperature is chosen to be within the range of the skin surface temperature of a human, such as from about 32.7 to 45.0° C. In an even more particular example, the composition is maintained at approximately 36.3° C. which is the median skin surface temperature calculated for resting adult humans.
- In vitro dissolution tests can be performed with or without relative motion between the sample and one of the disclosed compositions. In dissolution systems with motion, the disclosed composition can be agitated to increase contact of the test article with the composition and to simulate real-world motion of the test article when in contact with human skin. In dissolution systems without motion, both the test article and composition remain static throughout the test. A variety of agitation techniques are available, including shaking using a mechanical shaker or wrist action shaker, stirring using a magnetic stirrer, ultrasonic agitation, and rotation.
- The test liquids can contain varying ratios of sweat/sebum depending on study aims. On the skin, sebum spreads itself in a relatively thin, unevenly distributed sheet that ranges in thickness from less than 0.05 μm in sebum-poor areas to greater than 4 μm in sebum-rich areas such as the face. Sebum secretion rates vary among facial topographical regions, with climatic season, and with age. Thus, the ratio of sebum to sweat can be varied depending upon the desired thickness of sebum that is to be simulated.
- In some embodiments, the disclosed artificial sebum is used alone without the artificial sweat, and in other embodiments the artificial sweat is used alone without the artificial sebum, or in the substantial absence of any other test compositions. For example, when modeling the release of a chemical (such as a dye) from materials in contact with the soles of the feet (rubber sandals, socks, etc.) where sebum glands are absent, a sweat-only formulation may be selected as more biologically relevant. In contrast, when modeling the dissolution of nanoparticles (such as zinc oxide used to coat fabrics for sun block applications) from cloth (such as a baseball cap or sun hat) in contact with the forehead, then a larger sebum component may be used to mimic the greater amounts of sebum present on the normal human forehead. For example, a large sebum component (on both a mass basis and thickness) can be achieved by placing the sebum composition directly onto the sample container rather than a filter.
- The disclosed artificial sebum formulations can also be used alone to characterize the release and subsequent partitioning and absorption of chemicals from materials in contact with skin. For example, the influence of sebum on substance partitioning and absorption can be studied in various skin models using the disclosed artificial sebum. In one example, testing of partitioning in sebum alone can be evaluated by the protocol described by Valiveti et al. (Intern. J. Pharmaceutics 346:10-16, 2008) with our comprehensive sebum formulation. Exemplary skin models include pig skin, organotypic skin cultures (which do not contain sebaceous glands), neonatal rodent skin and shed snake skin.
- The artificial SSFL disclosed herein has been found to have dissolution properties that are superior to currently widely used artificial sweat compositions. As illustrated in Example 10, cobalt powder dissolves to a much greater extent in the disclosed SSFL than it does in the artificial sweat composition used in the European CEN 1811 standard, which is the most widely used artificial sweat formulation today.
- Prior formulations of artificial sweat often lacked many constituents that have now been determined to be present in human sweat. For example, among 45 formulations of artificial sweat in use between 1940 and 2005, seven lacked sodium, eight lacked chloride, 41 lacked calcium, 38 lacked potassium, 44 lacked magnesium, and all lacked bicarbonate. Of all ionic constituents in human sweat, only sulfate, fluoride, and phosphorous were included in several formulations of artificial sweat. All identified artificial formulations lacked sulfur, bromine, cadmium, copper, iodine, iron, lead, manganese, nickel, and zinc. A total of 16 amino acids have been found in human sweat; however, only four artificial formulations included more than one amino acid. No vitamins were included in any formulation of artificial sweat. Only five artificial SSFL formulations included a sebum component.
- The disclosed artificial SSFL represents a comprehensive artificial sweat solution which includes 60 constituents identified in human sweat, as well as a representative sebum component. Of the 60 constituents, all but riboflavin were present in concentrations that corresponded to median values reported in human sweat. Despite containing 60 different constituents, including antioxidants such as ascorbic acid (vitamin C), this comprehensive artificial formulation (like all artificial formulations) lacks enzymatic free radical scavengers present in dynamic biological systems, e.g., Cu/Zn-super oxide dismutase and Mn-superoxide dismutase (Richelle et al., Br. J. Nutr. 96: 227-238, 2006).
- The artificial sebum component used in the disclosed SSFL formulation includes nine constituents that fall into the six lipid categories identified in human sweat: squalene, wax esters, triglycerides, free fatty acids, cholesterol esters, and free cholesterol. The disclosed artificial sebum formulation differs from formulation previously disclosed, such as the formulation proposed by Musial and Kubis (Polim. Med. 34: 17-30, 2004) as follows: squalene content is lowered to better approximate the median value in human sebum (10.6%); lanolin wax esters are replaced with palmityl palmitate and oleyl oleate and the content raised to match the median value in human sebum (25%); animal-derived triglycerides are replaced with commercially available tristearin and triolein; free fatty acid content is raised to match the median value in human sebum (28.3%) and oleic acid is included as an unsaturated component; cholesterol esters as cholesteryl oleate are added at median value in human sebum (2%); and free cholesterol (4%) content is unchanged.
- The disclosed artificial sebum formulation mimics the composition of human sebum by wt % of constituents. The presence of a representative sebum component coupled with a comprehensive sweat component that mimics its natural analogue provides a more robust SSFL than is currently available for investigating dissolution of chemicals in direct and prolonged contact with human skin. The disclosed artificial sebum formulations can also be used to characterize the release and subsequent partitioning and absorption of chemicals from materials in contact with skin. For example, the influence of sebum on substance partitioning and absorption can be studied in various skin models using the disclosed artificial sebum.
- The subject matter of the present disclosure is further illustrated by the following non-limiting Examples.
- This example provides a method of preparing a comprehensive artificial sweat formulation.
- All chemicals were ACS reagent grade, unless specified otherwise. Sodium sulfate, sodium iodide (certified grade), 1M ammonium hydroxide, sulfur (USP grade), lead reference solution (Certified grade), nickel reference solution (Certified grade), zinc reference solution (Certified grade), sodium bicarbonate, sodium phosphate anhydrous monobasic (USP grade), calcium chloride dihydrate, lactic acid, L-(+)-glutamic acid, 5N sodium hydroxide, oleic acid (NF grade), and methanol were from Fisher Scientific (Fair Lawn, N.J.). Sodium fluoride, sodium bromide, cadmium chloride anhydrous, copper(II) chloride dihydrate, iron sulfate heptahydrate, manganese(II) chloride, potassium chloride, phosphorous pentachloride, pyruvic acid, butyric acid, acetic acid, hexanoic acid, propionic acid, isobutyric acid, isovaleric acid, D(+)-glucose, DL-alanine, L-(+)-arginine, L-(+)-aspartic acid, L-(+)-citrulline, glycine, L-histidine, L-isoleucine, L-leucine, L-(+)-lysine monohydrochloride, L-(+)-ornithine monohydrochloride, L-phenylalanine, L-threonine, L-(−)-tryptophan, L-tyrosine, uric acid, urea, creatinine, creatine monohydrate, riboflavin, nicotinic acid, pyridoxine monochloride, L-(+)-ascorbic acid, inositol, choline chloride, squalene, stearic acid/palmitic acid, and chloroform were from Acros Organics (Geel, Belgium). Magnesium chloride hexahydrate, L-valine, thiamine monochloride, D-pantothenic acid, folic acid, ascorbate oxidase, p-aminobenzoic acid, tristearin (Technical grade), and Triolein were from MP Biomedicals, Inc. (Solon, Ohio). Sodium chloride, palmityl palmitate, oleyl oleate, cholesteryl oleate (Technical grade), cholesterol, and (±)-α-tocopherol (HPLC grade) were from Sigma-Aldrich (St. Louis, Mo.).
- Calibrated chloride (Model 9617BN, Thermo Electron Corp., Beverly, Mass.) and calcium (Model 9320, Thermo Electron Corp.) ion selective electrodes were used to determine the stability and potential reactivity of representative constituents of the artificial sweat during preparation. After the addition of each class of chemicals, chloride and calcium concentrations were measured and compared to concentration values predicted from the masses of constituents dissolved during the preparation. A decrease in constituent concentration from mass-predicted values would indicate a reactive solution, whereas a reading corresponding to the predicted value would infer stability. These ions were chosen for their ability to be detected in a solution with high ionic strength, whereas other ionic-selective electrodes (e.g., fluorine, bromine, potassium) would have experienced interference from other ions present in solution. Iron strips (Aquacheck Total Iron Test Strips, Environmental Test Systems, Elkhart, Ind.) were used to semi-quantitatively monitor the stability and potential reactivity of iron in artificial sweat, especially in the presence of ascorbic acid (May et al., Biochem. Pharmacol. 57: 1275-1282, 1998).
- To prepare one liter of the comprehensive artificial sweat, it was found to be helpful to start with a volume of water that was at least about 70-80% of the final desired volume of artificial sweat. This large initial volume was useful in promoting dissolution of the constituents of the artificial sweat. Hence to make a 1 L volume of artificial sweat, 800 mL of fully-aerated 18 megohm-cm distilled and deionized water was added to a 1000 mL Erlenmeyer flask, a magnetic stir bar was added to the flask, and the water was warmed to 36° C. using a stirrer/hotplate with a digital probe. Next, the desired masses of electrolytes and other ionic constituents (see Table 2) were added to the flask. Upon addition of the electrolytes and ionic constituents, the concentrations of chloride, calcium, and iron were measured to assess whether they matched predictions from weighing: 1.67×10−2 M chloride, 6.93×10−3 M calcium, and 0.54 ppm iron. Next, organic acids and carbohydrates were added to the solution (see Table 2) and the stability of chloride, calcium, and iron concentrations verified. Amino acids were added (see Table 2) then calcium and iron concentrations verified; chloride ion concentration was measured to determine if it matched the predicted value (1.7×10−2 M) from weighing electrolytes, ionic constituents, and hydrogen chloride salts of some amino acids. Nitrogenous substances were added (see Table 2) and chloride, calcium, and iron concentrations re-verified.
- Vitamin constituents were added to the solution last (see Table 2). Dehydroascorbic acid was prepared by oxidizing an equal molar concentration of ascorbic acid (described in Example 2 below).
- With the exception of riboflavin, nicotinic acid, and pantothenic acid, all vitamins dissolved rapidly in the solution. The concentration of riboflavin in human sweat ranges from 1.0×10−7 to 1.0 M, with a median 2.0×10−2 M (Stefaniak and Harvey, Toxicol. In Vitro 20: 1265-1283, 2006). Due to the extremely low solubility of riboflavin (0.3 g/L water), only a maximum dissolved concentration of 2.0×10−3 M could be achieved, which is within the range reported for human sweat but a factor of 10 lower than the median value. This riboflavin concentration in artificial sweat was two orders of magnitude greater than that predicted by the solubility of riboflavin in water, an enhancement that may be due to solutropic interactions of dissolved nicotinic acid and urea (Coffman and Kildsig, J. Pharm. Sci. 85: 951-954. 1996) in the artificial sweat. It would be possible to achieve higher levels of dissolved riboflavin in artificial sweat using riboflavin salts such as
riboflavin 5′-(dihydrogen phosphate), which has higher solubility (68 g/L water) at pH=5.6 than riboflavin.Riboflavin 5′-(dihydrogen phosphate) is endogenously present in humans as a cofactor in many enzymatic pathways. The excretion ofriboflavin 5′-phosphate, however, occurs only after hydrolysis to free riboflavin (Jusko and Levy, J. Pharm. Sci. 56: 58-62, 1967) and is therefore not to be expected as a constituent in sweat, so it was not used. Upon addition of riboflavin and folic acid, the solution color changed from slightly yellow to a vivid yellow. The added quantities of pantothenic and nicotinic acids did not dissolve completely, which resulted in a cloudy solution. - After the addition of all vitamins, the concentrations of calcium and iron were re-verified; chloride ion concentration was measured to determine whether it matched the predicted value (2.2×10−2 M) from weighing electrolytes, ionic constituents, and hydrogen chloride salts of some amino acids and vitamins. Finally, sodium and chloride levels were adjusted to match the median values in human sweat by addition of 5.8×10−2 g sodium chloride per liter of solution and the concentrations of calcium and iron re-verified. Chloride concentration was measured to verify that it matched the final predicted value (2.3×10−2 M) from weighing all constituent classes. The pH of the artificial sweat solution was raised from 3.8 (as prepared) to a final pH of 5.3 (as described in Example 3 below).
- The final composition of the artificial sweat formulation is shown in Table 2.
-
TABLE 2 Comprehensive artificial sweat formulation Constituents Mass (g/L) Primary electrolytes and ionic constituents Sodium Sulfate (Na2SO4) 5.83 × 10−2 Sodium Iodide (NaI) 1.06 × 10−5 Sodium Fluoride (NaF) 4.62 × 10−4 Sodium Bromide (NaBr) 2.37 × 10−4 Cadmium Chloride Anhydrous (CdCl2) 3.30 × 10−6 Copper (II) Chloride Dihydrate (CuCl2•2H2O) 1.60 × 10−4 Ammonium Hydroxide (NH4OH) 1.82 × 10−1 Sulfur (S) 7.37 × 10−2 Iron Sulfate Heptahydrate (FeSO4•7H2O) 2.72 × 10−3 Lead (Pb) - Reference Solution 1000 ppm 2.49 × 10−5 Manganese (II) Chloride (MnCl2) 1.38 × 10−4 Nickel (Ni) - Reference Solution 1000 ppm 2.46 × 10−5 Zinc (Zn) - Reference Solution 1000 ppm 8.50 × 10−4 Sodium Bicarbonate (NaHCO3) 2.52 × 10−1 Potassium Chloride (KCl) 4.55 × 10−1 Magnesium Chloride Hexahydrate (MgCl2•6H2O) 1.67 × 10−2 Sodium Phosphate Anhydrous Monobasic (NaH2PO4) 4.84 × 10−2 Calcium Chloride Dihydrate (CaCl2•2H2O) 7.65 × 10−1 Phosphorous Pentachloride (PCl5) 2.71 × 10−3 Sodium Chloride (NaCl)1 5.84 × 10−2 Organic acids and carbohydrates Lactic acid (CH3CH(OH)COONa) 1.57 × 100 Pyruvic acid (C3H4O3) 1.59 × 10−2 Butyric acid (C4H8O2) 2.11 × 10−4 Acetic acid (C2H4O2) 7.81 × 10−3 Hexanoic acid (C6H12O2) 1.05 × 10−4 Propionic acid (C3H6O2) 2.59 × 10−4 Isobutyric acid (C4H8O2) 7.05 × 10−5 Isovaleric acid (C5H10O2) 1.12 × 10−4 D(+)-Glucose (C6H12O6) 3.06 × 10−2 Amino acids DL-Alanine (C3H7NO2) 5.11 × 10−2 L-(+)-Arginine (C6H14N4O2) 1.36 × 10−1 L-(+)-Aspartic acid (C4H7NO4) 4.53 × 10−2 L-(+)-Citrulline (C6H13N3O3) 7.01 × 10−2 L-(+)-Glutamic acid (C5H9NO4) 5.44 × 10−2 Glycine (C2H5NO2) 2.93 × 10−2 L-Histidine (C6H9N3O2) 8.07 × 10−2 L-Isoleucine (C6H13NO2) 2.23 × 10−2 L-Leucine (C6H13NO2) 2.75 × 10−2 L-(+)-Lysine Monohydrochloride (C6H14N2O2•HCl) 2.74 × 10−2 L-(+)-Ornithine Monohydrochloride (C5H12N2O2•HCl) 2.53 × 10−2 L-Phenylalanine (C9H11NO2) 2.13 × 10−2 L-Threonine (C4H9NO3) 5.36 × 10−2 L-(−)-Tryptophan (C11H12N2O2) 1.12 × 10−2 L-Tyrosine (C9H11NO3) 3.08 × 10−2 L-Valine (C5H11NO2) 2.93 × 10−2 Nitrogenous Substances Ammonium2 — Uric acid (C5H4N4O3) 9.92 × 10−3 Urea (CH4N2O) 6.01 × 10−1 Creatinine (C4H7N3O) 9.50 × 10−3 Creatine Monohydrate (C4H9N3O2•H2O) 2.24 × 10−3 Vitamins Thiamine Hydrochloride (C12H17ClN4OS•HCl) 1.69 × 100 Riboflavin (C17H20N4O6) 7.53 × 10−1 Nicotinic Acid (C6H5NO2) 5.05 × 101 D-Pantothenic Acid (C9H17NO5) 2.85 × 101 Pyridoxine Hydrochloride (C8H11NO3•HCl) 2.06 × 10−6 Folic Acid (C19H19N7O6) 7.06 × 10−6 L-(+)-Ascorbic Acid (C6H8O6) 1.76 × 10−3 Dehydroascorbic Acid 1.91 × 10−3 Inositol (C6H12O6) 2.88 × 10−3 Choline Chloride (C5H14NOCl) 3.63 × 10−3 p-Aminobenzoic Acid (C7H7NO2) 9.73 × 10−6 1Added last to adjust sodium and chloride content of artificial sweat formulation to match median values in human sweat 2Added as ammonium hydroxide with primary electrolytes and ionic constituents - This example provides a method of preparing dehydroascorbic acid from asorbic acid.
- To prepare dehydroascorbic acid calibration standards, six 100 mL solutions of ascorbic acid were prepared at concentrations that ranged from 1×10−2M through 1×10−7 M, using decade dilutions. The ascorbic acid solutions were completely oxidized to dehydroascorbic acid by adding 200 μL of the enzyme ascorbate oxidase to each solution, then incubating at 37° C. for 30 minutes. Using a spectrophotometer (
Spectronic 20 Genesys, Spectronic Instruments, Inc., Rochester, N.Y.), a calibration curve was prepared by measuring the absorbance of the dehydroascorbic acid standard solutions at 346 nm. - To prepare one liter of artificial sweat that contained dehydroascorbic acid at the median concentration in human sweat, 1.7×10−2 g ascorbic acid was dissolved in 100 mL of 18 megohm-cm distilled and deionized water. Next, 200 μL of ascorbate oxidase was added to the solution and it was incubated for 30 minutes at 37° C., followed by verification of the concentration of dehydroascorbic acid using the calibrated spectrophotometer. Note that after verifying the concentration of dehydroascorbic acid, the solution can be incubated at 37° C. for three days to render the ascorbate oxidase inactive, thus eliminating the possibility of oxidizing ascorbic acid present in sweat.
- This example provides a method for increasing the pH of an artificial sweat solution.
- The pH of the artificial sweat solution was raised from 3.8 (as prepared) to a final pH of 5.3 by adding 5 M sodium hydroxide dropwise while monitoring using a calibrated pH electrode (InLab 413, Mettler-Toledo, Schwerzenbach, Switzerland) connected to a multi-meter (Seven Multi, Mettler-Toledo). Use of 5 M sodium hydroxide caused any undissolved vitamins to go completely into solution. The final volume of the solution was then brought up to 1.0 L using 18 megohm-cm distilled and deionized water and the final pH verified. To minimize opportunity for microbial growth, the final sweat solution was filtered through a 0.2 μm pore size filter (Cat. No. SCGVU11RE, Millipore Corp., Billerica, Mass.). Additional studies demonstrated the sweat formulation could be adjusted to a pH up to 6.5 while maintaining the integrity of the solution. Additionally, the batch volume has been successfully scaled up from 1.0 L to 10.0 L.
- This example provides a method of preparing an artificial sebum formulation.
- Artificial sebum was prepared by dissolving nine different lipid constituents (see Table 3) in a sterilized 1000 mL Erlenmeyer flask that contained 500 mL of a 2:1 co-solvent mixture of chloroform and methanol while stirring continuously using a magnetic stir bar and stir plate.
-
TABLE 3 Artificial sebum formulation Constituent Saturation Chemical Mass (g) Squalene Squalene 0.5151 Wax esters Saturated Palmityl Palmitate 0.9718 Unsaturated Oleyl Oleate 0.2430 Triglycerides Saturated Tristearin 1.0690 Unsaturated Triolein 0.5345 Free Fatty Acids Saturated Stearic/Palmitic Acids 0.6876 Unsaturated Oleic Acid 0.6876 Cholesterol Esters Cholesteryl Oleate 0.0972 Free Cholesterol Cholesterol 0.1944 Vitamin E (±)-α-Tocopherol 0.0050 - This example demonstrates that the optimal storage conditions for the disclosed artificial sweat and sebum formulations as well as the shelf-life of the disclosed artificial SSFL.
- Dissolution of fine materials (e.g., particles) is often evaluated by isolating the test material between two filters in a dissolution chamber, then immersing the chamber in a model liquid. Thus, to characterize the stability of artificial sweat and artificial sebum in combination, the sebum component was deposited onto mixed cellulose ester filters by immersing each filter into the sebum solution, then allowing the chloroform:methanol co-solvent to evaporate off at ambient temperature and atmosphere. Alternatively, for large test articles, the artificial sebum could be deposited directly onto the walls of the container used to house the solvent and test article. It was assumed that artificial sebum was evenly deposited on the top and bottom surfaces of each filter. Modeling filters as a geometric cylinder, the thickness of artificial sebum was estimated to be 1.0 μm, which is consistent with the thickness of human sebum on skin. Thickness calculations were verified by visual inspection of uncoated and sebum-coated filters using a scanning electron microscope (SEM). In the SEM, the artificial sebum appeared as a hazy coating of approximately 1 μm at the edge of the filter. Each sebum-coated filter was immersed in 80-mL artificial sweat contained in a polypropylene plastic cup with screw cap lid, then pH, chloride, calcium, and iron values were monitored twice daily for 14 days as previously described.
- The stability of the novel artificial SSFL sweat and sebum components was tested in combination and individually. To characterize the stability of sweat and sebum in combination, 47-mm mixed cellulose ester filters were coated with a 1 μm thick layer of artificial sebum. On human skin, sebum forms a 0.5 to >4.0 μm thick layer. Each sebum-coated filter was immersed in 80 mL of artificial sweat maintained at 36.3° C., the median temperature reported for human skin. The pH, [Cl−], [Ca+2], and [Fe] of the artificial sweat, monitored twice daily for two weeks were: 5.3±0.1, 3.0±0.1×10−2 M, 7.4±0.1×10−3 M, and 0.5 ppm, respectively at 36.3° C.
- The stock artificial sweat and sebum formulations were also characterized individually under different storage conditions to estimate shelf life. The pH, chloride, calcium, and iron values of the stock artificial sweat were monitored at room temperature (23° C.) daily for 14 days. The [Cl−], [Ca+2], and [Fe] levels of the artificial sweat remained equivalent to median values in human sweat over a two week characterization period (data not shown) when stored at room temperature (23° C.). During this same period, the artificial sweat had a mean pH of 5.3±0.1 at 23° C. The pH of human sweat ranges from 2.1 to 8.2, with a median value of 5.3, but varies due to endogenous (e.g., age, ethnicity, sebum content, sweat content) and exogenous (e.g., use of cosmetics, soaps, occlusive dressings) factors. The formulation of comprehensive sweat described herein has a pH that mimics the median value of human sweat; however, this formulation may not be suitable for analyzing the behavior of materials in artificial SSFL under more acidic conditions. If the pH of this artificial sweat formulation was below 4.8, precipitation of salts occurred rapidly.
- Monitoring of the pH of the stock artificial sweat solution was stopped on day 14; however, the solution was visibly unchanged until day 18 when microbial growth appeared on the surface of the liquid. Stability of the artificial sweat at ambient temperature may be enhanced by filtering the liquid to remove bacteria and ensuring the sterility of all glassware used to transfer and store the sweat. Filtering the artificial sweat with a 0.2 micron pore filter is an example of a filtration method that substantially removes the bacteria. Refrigeration of the artificial sweat is not recommended; when stored at 4° C., precipitation and/or recrystallization of constituents occurred. Hence in certain disclosed methods, the sweat composition is stored while being maintained at temperatures close to body temperature, for example 35-38° C., such as 36-37° C.
- Initially, stability of the stock artificial sebum was evaluated by visually monitoring solution color and clarity over a two week period. Two storage conditions for the sebum solution were used: ambient atmosphere and temperature versus displacement of air in the flask headspace with nitrogen gas and refrigeration at 4° C. When stored at room temperature and atmosphere, the sebum solution oxidized in less than 24 hours as indicated by a color change from slightly white to yellow, presumably due to the oxidation of triolein. To inhibit oxidation of the prepared stock sebum solution, the flask was evacuated and the solution blanketed with nitrogen, then stored at 4° C. When stored under these latter conditions, the stock sebum appeared to be stable for over two weeks. Subsequent quantitative studies were performed using thin layer chromatography and confirmed that the sebum constituents maintained dry or in the chloroform:methanol solution at 4° C. were stable through 28 days in the presence and absence of vitamin E. In the presence of vitamin E, the artificial sebum formulation could be used for 28 days at 23° C., a temperature similar to human skin (Example 10).
- These studies demonstrate that the disclosed artificial SSFL formulation was a chemically-stable artificial SSFL with a well-buffered pH that can be used in studies of the potential release and percutaneous absorption of chemicals that dissolve from articles in contact with skin. These studies also demonstrate that optimal storage conditions for the disclosed artificial sebum formulation include storage under a nitrogen blanket at a reduced temperature (e.g., 4° C.).
- This example provides a detailed protocol for preparing artificial sweat.
- The artificial sweat formulation was prepared by providing 80% of the desired final volume of 18MΩ distilled and deionized water to a large carboy (4.8 L water for 6 L batch or 7.2 L water for 9 L batches). A stir bar and temperature probe were placed in the container then stirring begun at 450 rpm on a magnetic stir plate while warming to 36.3° C. (Model 11-800-495SHP, Fisher Scientific, Dubuque, Iowa). The inlet side of an in-line HEPA filter (HEPA-CAP 36, Whatman Inc., Florham Park, N.J.) was connected to an air supply and an aeration stone was connected to the outlet side of the filter. An aeration stone was placed in the water of the carboy and air bubbled into the liquid for 1 hour to saturate it with air.
- A weighing dish was placed on a calibrated microbalance (Model XS205, Mettler-Toledo, Greifensee, Switzerland). Each constituent (beginning with sodium sulfate) was weighed out or pipeted in the appropriate mass or volume of each constituent, and the weighed mass of the constituent recorded. The weighed mass was then transferred to the appropriate carboy then the weighing dish rinsed with water to ensure complete transfer into beaker. Each of the constituents was transferred in this manner, in the order in listed in Table 4 below.
- The mass or volume of some chemical constituents in the table were too small to be weighed with a desired accuracy on the balance or dispensed by the pipets, so the protocol was modified by preparation of concentrated solutions that were pipetted into a beaker:
- a. Sodium Iodide: Dissolve 0.010 g NaI in 0.050 L water
b. Sodium Fluoride: Dissolve 0.020 g NaF in 0.050 L water
c. Sodium Bromide: Dissolve 0.010 g NaBr in 0.050 L water
d. Cadmium Chloride Anhydrous: Dissolve 0.010 g CdCl2 in 0.050 L water
e. Copper Chloride Dihydrate: Dissolve 0.010 g CuCl2.2H2O in 0.050 L water
f. Lead Reference Solution: Pipet 1.0 mL lead reference solution in 0.050 L water
g. Manganese Chloride: Dissolve 0.010 g MnCl2 in 0.050 L water
h. Nickel Reference Solution: Pipet 1.0 mL nickel reference solution in 0.050 L water
i. Hexanoic Acid: Pipet 1.0 mL hexanoic acid in 0.050 L water
j. Isobutyric Acid: Pipet 1.0 mL isobutyric acid in 0.050 L water
k. Isovaleric Acid: Pipet 1.0 mL isovaleric acid in 0.050 L water
l. Creatinine: Dissolve 1.000 g creatinine in 0.250 L water
m. Creatine monohydrate: Dissolve 1.000 g creatinine monohydrate in 0.250 L water
n. Pyridoxine Hydrochloride: Dissolve 0.010 g pyridoxine hydrochloride in 0.050 L water
o. Folic Acid: Dissolve 0.010 g folic acid in 0.050 L water
p. Ascorbic Acid: Dissolve 0.050 g ascorbic acid in 0.050 L water
q. Inositol: Dissolve 0.010 g inositol in 0.050 L water
r. Choline Chloride: Dissolve 1.000 g choline chloride in 0.050 L water
s. p-Aminobenzoic Acid: Dissolve 0.010 g p-aminobenzoic acid in 0.050 L water - The only modification of this procedure was for addition of the vitamins, in which the protocol was modified by placing 50 mL of 5N sodium hydroxide in a 100 mL beaker and stirring it at 450 rpm, then adding pantothenic acid to the beaker until the solution was milky in appearance (˜10 mg). The remaining pantothenic acid powder was added in small increments to the 2 L beaker containing the sweat solution and went into solution. Then the riboflavin was added to the 2 L beaker, whereupon the solution turned orange-yellow. Next, the sodium hydroxide/pantothenic acid solution was added to the 2 L beaker in aliquots of ˜10 mL. To rinse the 100 mL beaker, the remaining vitamins (in liquid form) were added to the beaker along with 50 mL dehydroascorbic acid. The solution was transferred to the 2 L beaker with the sweat then rinsed a second time with 50 mL DHA. Finally, nicotinic acid was added incrementally (˜10 mg at a time) and solution began to clear as constituent was added. The stirrer was turned off, then pH was raised to 5.3 by adding sodium hydroxide 1 mL at a time with stirring after each addition of base. After addition of the vitamins, the warm solution was stirred overnight.
-
TABLE 4 Preparation of artificial sweat (pH 5.3) Sweat Constituent Mass (g/L) Volume (μL/L) Primary electrolytes and ionic constituents Sodium Sulfate (Na2SO4) 0.05826 — Sodium Iodide (NaI) — 54.6 Sodium Fluoride (NaF) — 2310.9 Sodium Bromide (NaBr) — 1185.6 Cadmium Chloride Anhydrous (CdCl2) — 16.4 Copper (II) Chloride Dihydrate (CuCl2•2H2O) — 803.4 1M Ammonium Hydroxide (NH4OH) — 186.0 Sulfur (S) 0.07374 — Iron Sulfate Heptahydrate (FeSO4•7H2O) 0.00272 — Lead (Pb) - Reference Solution 1000 ppm — 1243.0 Manganese (II) Chloride (MnCl2) — 691.4 Nickel (Ni) - Reference Solution 1000 ppm — 1232.0 Zinc (Zn) - Reference Solution 1000 ppm — 0.77 Sodium Bicarbonate (NaHCO3) 0.25203 — Potassium Chloride (KCl) 0.45469 — Magnesium Chloride Hexahydrate (MgCl2•6H2O) 0.01667 — Sodium Phosphate Anhydrous Monobasic (NaH2PO4) 0.04836 — Calcium Chloride Dihydrate (CaCl2•2H2O) 0.76450 — Phosphorous Pentachloride (PCl5) 0.00271 — Sodium Chloride 0.05844 — Organic acids and carbohydrates Sodium Lactate (CH3CH(OH)COONa) — 2011.0 Pyruvic acid (C3H4O3) — 12.7 Butyric acid (C4H8O2) — 0.22 Acetic acid (C2H4O2) — 7.43 Hexanoic acid (C6H12O2) — 5.70 Propionic acid (C3H6O2) — 0.26 Isobutyric acid (C4H8O2) — 3.70 Isovaleric acid (C5H10O2) — 6.00 D(+)-Glucose (C6H12O6) 0.03063 — Amino acids DL-Alanine (C3H7NO2) 0.05114 — L-(+)-Arginine (C6H14N4O2) 0.13588 — L-(+)-Aspartic acid (C4H7NO4) 0.04525 — L-(+)-Citrulline (C6H13N3O3) 0.07008 — L-(+)-Glutamic acid (C5H9NO4) 0.05444 — Glycine (C2H5NO2) 0.02927 — L-Histidine (C6H9N3O2) 0.08068 — L-Isoleucine (C6H13NO2) 0.02230 — L-Leucine (C6H13NO2) 0.02755 — L-(+)-Lysine Monohydrochloride (C6H14N2O2•HCl) 0.02740 — L-(+)-Ornithine Hydrochloride (C5H12N2O2•HCl) 0.02529 — L-Phenylalanine (C9H11NO2) 0.02148 — L-Threonine (C4H9NO3) 0.05360 — L-(−)-Tryptophan (C11H12N2O2) 0.01123 — L-Tyrosine (C9H11NO3) 0.03080 — L-Valine (C5H11NO2) 0.02928 — Nitrogenous Substances Ammonium1 — Uric acid (C5H4N4O3) 0.00992 — Urea (CH4N2O) 0.60060 — Creatinine (C4H7N3O) — 1357.0 Creatine Monohydrate (C4H9N3O2•H2O) — 447.8 Vitamins Thiamine Hydrochloride (C12H17ClN4OS•HCl) 1.68630 — Riboflavin (C17H20N4O6) 0.7527 — Nicotinic Acid (C6H5NO2) 50.47510 — D-Pantothenic Acid (C9H17NO5) 28.50120 — Pyridoxine Hydrochloride (C8H11NO3•HCl) — 10.3 Folic Acid (C19H19N7O6) — 35.3 L-(+)-Ascorbic Acid (C6H8O6) — 877.2 Dehydroascorbic Acid2 — 100.0 mL/L Inositol (C6H12O6) — 1441.4 Choline Chloride (C5H14NOCl) — 726.3 p-Aminobenzoic Acid (C7H7NO2) — 47.3 1Added as ammonium hydroxide with primary electrolytes and ionic constituents 2Use stock solution stored in 4° C. refrigerator - To verify the final composition of the artificial sweat, the expected chloride (Cl−) concentration was calculated in each of the three artificial sweat solutions using a chloride ion selective electrode (Cl− ISE) (Model 9617BN, Thermo Electron Corp) connection to mV meter (Model AR15, Fisher Scientific). The expected calcium concentration was also calculated and measured using a calcium ion selection electrode (Ca+2 ISE) (Model 9320, Thermo Electron Corp) connection to mV meter (Model AB15, Fisher Scientific). The iron concentration was calculated and then measured by adding one foil packet of iron reducing powder pillows (AquaChek® total iron test strips, Environmental Test Systems, Elkhart, Ind.) to each vial with artificial sweat solution. The vial was capped and shaken for 5 seconds or until powder dissolves. A test strip was dipped in the solution and compared to a color chart on the test strip bottle.
- This example provides a protocol for preparing sebum coated filters for use in dissolution studies.
- The sebum solution in an organic solvent (lipids dissolved in 2:1 chloroform methanol) was removed from a 4° C. refrigerator and placed on a hotplate/stirrer. Valves were opened on the container to purge nitrogen gas in the flask, and the solution was gently warmed until the solution turned clear and all solids dissolved. Whatman 541 ashless filter circles were weighed and placed on a screen of a uniquely identified dissolution chamber. After the sebum had cleared, 50 mL of solution were poured into a clean wide-mouth beaker, and each Whatman 541 ashless filter circle was dipped in the sebum with tweezers then placed on top of a screen in a dissolution chamber. Solvent was allowed to evaporate for 30 minutes to yield sebum on filter; each sebum-coated filter was weighed to determine the weight increase.
- When finished with the sebum solution, its flask headspace was purged and replaced with N2 gas to inhibit oxidation of lipids. Purging was performed by stoppering the flask and closing all valves. One end of the tubing was connected to a vacuum for a few seconds and the valve then closed. The tubing was then connected at one end to vacuum and at the other end to an N2 gas canister. The flask of sebum solution was then refrigerated at 4° C.
- This example provides a protocol for preparing filter sandwiches for use in dissolution studies.
- A sebum-coated 47 mm Whatman 541 ashless filter circle was placed on top of a 47 mm nitrocellulose filter having a 0.025-μm pore size. The two filters (with the sebum coated filter on top) were placed on the screen resting in the lower ring of the dissolution chamber (Cat. No. 06-401, In-Tox Products, LLC, Moriarity, N. Mex.).
- The filters and chamber half on the microbalance were tared. Using a clean spatula, the required minimum mass of bulk or size-separated powder to be dissolution tested was added to the sebum-coated filter.
- As illustrated in Table 5, powder masses were adjusted to yield equivalent masses of cobalt in all samples; the mass of tungsten will be equivalent in the W (tungsten), WC (tungsten carbide), and add-mix powders, but not the spray dryer or chamfer material.
-
TABLE 5 Powder masses of hard metal powder samples. Powder Mass (g) Size W WC Co Admix Spray dry Chamfer Bulk 0.0460 0.0489 0.0032 NA NA NA Stage 1 0.0460 0.0489 0.0032 0.0489 0.0252 0.0278 Stage 2 0.0460 0.0489 0.0032 0.0489 0.0252 —a Stage 3 0.0460 0.0489 0.0032 0.0489 — — aInsufficient mass of material for planned dissolution study - The actual mass of powder for each sample was recorded, and a second 0.025-μm pore nitrocellulose filter was placed on top of the powder and sebum-coated Whatman 541 to encase the material. An O-ring was placed on top of the filter assembly, the top half of the chamber was seated on the assembly, and the assembly was screwed together using 4 nylon screws to form a particle-tight seal around the perimeter of the filter sandwich. Each static dissolution chamber was stored in a clean, re-sealable plastic bag that was marked with the contents and sample number.
- Additional filter sandwiches were made without powder at a ratio of 1 in 10 for use as blanks. One undosed sandwich was placed into a static dissolution chamber then stored in a clean, re-sealable plastic bag. Bulk tungsten, tungsten carbide, or cobalt powder was used to spike filter sandwiches containing known amount of particles (using the same masses as experimental samples) at a ratio of 1 in 10 per material type.
- This example demonstrates dissolution testing in artificial SSFL.
- A 0.22 μm pore filter was used to filter 1 L of artificial sweat solution using a sterile 1 L filter unit and vacuum. With a sterile pipet, 80 mL of artificial sweat was added to each appropriately labeled autoclaved polypropylene jar with a screw-top lid. The lid was screwed on each jar and all jars were placed in the incubator at 36.3° C. for 3 hours to equilibrate solvent temperature. After 3 hours, the jars were removed one at a time from the incubator, the lid unscrewed, a static dissolution chamber placed in the artificial sweat. For each solvent formulation, triplicate samples of cobalt powder were studied. Using a sterile pipet, 80 mL of artificial sweat was added to the empty autoclaved polypropylene jars and placed in the incubator to equilibrate solvent prior to the next scheduled change out. The container was covered and returned to the incubator.
- At 10 pre-determined time points (1, 4, 8, 12, 16, 20, 24, 32, 40, and 48 hours) samples of solvent from each container were collected for analysis of dissolved cobalt and tungsten concentration. The purpose of measuring masses of dissolved cobalt and tungsten at multiple time points was to investigate the dissolution kinetics of these powders. At each time point, a sample jar and a jar containing equilibrated solvent were removed one at a time from the incubator and the lids unscrewed. Using plastic forceps, the dissolution chamber was removed from the solvent and shaken to remove excess liquid. The powder-exposed liquid was transferred into a clean numbered borosilicate glass sample jar and a record made of the sample contents, time, and any other pertinent data. Each borosilicate glass jar was maintained at a temperature of ˜36° C. The dissolution chamber was returned to its static dissolution chamber in its appropriate container, immersed in fresh temperature-equilibrated solvent, covered with the lid, and returned to the incubator. These steps were repeated until the solvent had been changed in all samples.
- The pH of solvent in each borosilicate glass sample jar was measured at 36.3° C. After determining the pH of all samples, the jars were placed in a −80° C. freezer for storage until analysis by spectroscopy.
- The quality control samples were treated in a similar manner using the filter sandwiches containing sebum-coated filters at a ratio of 1 in 10 prepared dissolution chambers. The artificial sweat was added at the same pre-determined time points as the experimental samples. Samples were spiked with tungsten and cobalt powder at a ratio of 1 in 10 prepared dissolution chambers.
- All experimental and quality control samples were submitted blind (without identification of the sample type or study design) to a commercial laboratory for quantification of cobalt content. Blinded quality control samples included field blank samples, reagent blank samples (artificial SSFL, artificial CEN sweat, or filters). All samples were analyzed by US Occupational Safety and Health Administration (US OSHA) Method ID-213: Tungsten and cobalt in workplace atmospheres (ICP analysis), a fully-validated standard method for quantification of soluble and insoluble cobalt. Artificial SSFL and CEN sweat samples, which contained dissolved cobalt and/or tungsten, were analyzed without digestion to quantify the mass of dissolved metals (MD). The matrix-specific method limits of detection (LOD) and limits of quantification (LOQ) for liquid samples are provided in Table 6.
-
TABLE 6 Matrix-specific method LOD and LOQ for liquid samples Co (mg/L) Formulation LOD LOQ NIOSH 0.6 2 CEN 0.3 0.83 -
FIG. 1 summarizes the total masses of cobalt dissolved during the 48 hour dissolution study using three variations of artificial SSFL (full formulation, without glycine, and without phosphate). One-way analysis of variance analysis revealed that dissolution rates were similar among these three variations of artificial SSFL (p=0.16).FIG. 2 summarizes the total masses of tungsten dissolved from tungsten metal powder and tungsten carbide powder and the total mass of cobalt dissolved from cobalt metal powder in three variations of the full formulation of artificial SSFL (pH 5.3, 5.9, and 6.5) and the European Committee for Standardization (CEN) artificial sweat formulation described in EN 1811, which is a simple solution of 0.5% NaCl, 0.1% urea and 0.1% lactic acid, with a pH adjusted to 6.5 using NH4OH. - On a mass basis, the percentage of tungsten powder dissolved in SSFL at all pH values were greater than in the CEN 1811 sweat formulation. Of particular importance was that dissolution of tungsten in the full SSFL formulation with pH 6.5 was a factor of two higher than in the CEN 1811 formulation with the same pH but different chemical composition. The difference in dissolution was even more pronounced for cobalt powder. Dissolution of cobalt in the full SSFL formulation with pH 6.5 was a factor of four higher than in the CEN 1811 formulation with the same pH but different chemical composition. For the very poorly soluble tungsten carbide material, observed dissolution rates do not appear to be influenced by solvent pH or composition.
- This example demonstrates a formulation of artificial sebum that can be used as a component of SSFL in studies for characterizing the release and subsequent partitioning and absorption of chemicals from materials in contact with skin.
- Lipids and formulation of synthetic sebum. Cholesteryl oleate, oleoyl oleate, palmityl palmitate, cholesterol and vitamin E ((±)-α-tocopherol) were purchased from Sigma-Aldrich (St. Louis, Mo.). Squalene and stearic acid were from Acros Organics (Geel, Belgium). Triolein and tristearin were purchased from MP Biochemicals (Solon, Ohio), and oleic acid was from Fisher Scientific (Fairlawn, N.J.). The artificial sebum summarized in Table 3 was based on a formulation by Musial and Kubis (Polim. Med., 34: 17-30, 2004) that was modified to closely match median values of lipid constituents in human sebum and used more realistic proportions of saturated and monounsaturated components estimated from Stefaniak and Harvey (Toxicol. In Vitro 20: 1265-1283, 2006). All nine lipids were dissolved in a 2:1 co-solvent mixture of chloroform and methanol and divided into two portions, one of which received vitamin E at 0.1% by weight to mimic human sebum content. After combining and mixing, portions of lipid solution were transferred to 16×125 mm glass tubes equipped with Teflon-lined screw caps. One set of tubes with lipid solution was maintained at 4° C. to characterize storage using refrigeration. Solvent was removed from the remaining tubes by evaporation under nitrogen and the tubes with lipids split into two sets, one was maintained at 4° C. to characterize storage and the other at 32° C. to characterize use conditions (e.g., mimic human skin conditions). For each set, triplicate samples were harvested for analysis at 2, 4, 7, 9, 11, 14, 16, 18, 21, 23, 25, and 28 days.
- Thin-layer chromatography. All samples were analyzed using thin layer chromatography. Glass plates (20×20 cm) coated with 0.25-mm-thick silica gel G (Adsorbosil-plus-1; Alltech Associates; Deerfield Ill.) were washed with chloroform:methanol, 2:1, activated in a 110° C. oven, and the adsorbent was scored into 6-mm-wide lanes. Calibrated glass capillaries were used to apply 5 μl samples two to three cm from the bottom edge of the plate, and the chromatogram was developed to 20 cm with hexane, followed by toluene to 20 cm, followed by hexane:ethyl ether:acetic acid, 70:30:1, to 12 cm. After development, chromatograms were air dried, sprayed with 50% sulfuric acid, and slowly heated to 220° C. on an aluminum slab on a hot plate. After two hrs, charring was complete, and the chromatograms were quantitated by photodensitometry. Thin layer chromatography analyses demonstrated that lipid reagents (a) squalene, (b) cholesteryl oleate, (c) cholesterol, (d) palmityl palmitate, (e) oleyl oleate, (f) tristearin, (g) triolein, (h) stearic acid, and (i) oleic acid) were pure materials. These analyses also indicated that under various conditions the individual lipids were chemically-stable (no cross-reactions) and that the formulation could be stored refrigerated for 28 days without loss of chemical integrity. For example, the sebum constituents maintained dry or in the chloroform:methanol solution at 4° C. were stable through 28 days in the presence and absence of vitamin E. In the presence of vitamin E, the artificial sebum formulation could be used for 28 days at a temperature similar to human skin. For example, all sebum lipids maintained dry at 32° C. were also stable in the presence of vitamin E; however, squalene oxidized completely by day 21 in the absence of vitamin E.
- These studies demonstrate that the disclosed artificial formulation of sebum is representative of native human sebum (e.g., the artificial sebum formulation included all six lipid classes present in human sebum, the lipid content closely matched median values in human sebum, and the proportions of saturated and unsaturated wax esters and triglycerides closely matched human sebum).
- In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Claims (18)
1. A composition comprising: electrolytes, inorganic constituents, organic acids, carbohydrates, nitrogenous substances and vitamins in concentrations found in human sweat, and maintained at a pH of 4.8-5.8.
2. The composition of claim 1 , further comprising a sebum formulation, wherein the sebum formulation comprises squalene, wax esters, triglycerides, free fatty acids, cholesterol esters, free cholesterol and vitamin E in concentrations found in human sebum.
3. The composition of claim 1 , wherein the electrolytes comprise bicarbonate, and the ionic constituents comprise sulfur, bromine, cadmium, copper, iodine, iron, lead, manganese, nickel and zinc.
4. The composition of claim 3 , wherein the electrolytes comprise sodium, chloride, calcium, potassium, magnesium, phosphate and bicarbonate; the ionic constituents comprise sulfate, sulfur, fluoride, phosphorous, bromine, cadmium, copper, iodide, iron, lead, manganese, nickel, zinc; the organic acids comprise lactic acid, pyruvic acid, butyric acid, acetic acid, hexanoic acid, propionic acid, isobutyric acid, and isovaleric acid; the carbohydrates comprise glucose; the amino acids comprise alanine, arginine, aspartic acid, citrulline, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, ornithine, phenylalanine, threonine, tyrosine, and valine; the nitrogenous substances comprise ammonium, uric acid, creatinine and creatine; and the vitamins comprise thiamine, riboflavin, nicotinic acid, pathothenic acid, pyridoxine, folic acid, ascorbic acid, dehydroascorbic acid, inositol, choline and p-aminobenzoic acid, at a pH of 5.1-5.5.
5. The composition of claim 4 , wherein the electrolytes are present in a molar concentration of Na (3.0-3.5×10−2), Cl (2.0-2.5×10−2), Ca (5.0-5.5×10−3), K (5.8-6.2×10−3), Mg (8.0-8-5×10−5), PO4 (2.8-3.4×10−4), and HCO3 (2.7-3.3×10−3); the ionic constituents are present in a concentration of SO4 (3.9-4.5×10−4), S (2.0-2.6×10−3), F (0.8-1.4×10−5), P (1.0-1.6×10−5), Br (2.0-2.6×10−6), Cd (1.5-2.1×10−8), Cu (9.1-9.7×10−7), I (6.8-7.4×10−8), Fe (9.5-10.1×10−6), Pb (0.9-1.5×10−7), Mn (0.8-1.4×10−6), Ni (3.9-4.5×10−7), and Zn (1.0-1.6×10−5); the organic acids and carbohydrates are present in concentrations of lactic acid (1.1-1.7×10−2), pyruvic acid (1.5-2.1×10−4), butyric acid (2.1-2.7×10−6), acetic acid (1.0-1.6×10−4), hexanoic acid (8.7-9.3×10−7), propionic acid (3.2-3.8×10−6), isobutyric acid (7.7-8.3×10−7), isovaleric acid (0.8-1.4×10−6), and glucose (1.4-2.0×10−4); the amino acids are present in concentrations of alanine (3.3-3.9×10−4), arginine (7.5-8.1×10−4), aspartic acid (3.1-3.7×10−4), citrulline (3.7-4.3×10−4), glutamic acid (3.4-4.0×10−4), glycine (3.6-4.2×10−4), histidine (4.9-5.5×10−4), isoleucine (1.4-2.0×10−4), leucine (1.8-2.4×10−4), lysine (1.2-1.8×10−4), ornithine (1.2-1.8×10−4), phenylalanine (1.0-1.6×10−4), threonine (4.2-4.8×10−4), tryptophan (5.2-5.8×10−5), tyrosine (1.4-2.0×10−4), and valine (2.2-2.8×104); the nitrogenous substances are present in a concentration of NH3 (4.9-5.5×10−3), urea (0.7-1.3×10−2), uric acid (5.6-6.2×10−5), creatinine (8.1-8.7×10−5), and creatine (1.2-1.8×10−5); the vitamins are present in a concentration of thiamine (4.7-5.3×10−3), riboflavin (1.7-2.5×10−3), niacin (3.8-4.4×10−1), pantothenic acid (1.0-1.6×10−1), pyridoxine (0.7-1.3×10−8), folic acid (1.3-1.9×10−8), ascorbic acid (0.7-1.3×10−5) and/or its oxidation product dehydroascorbic acid (0.8-1.4×10−5), inositol (1.3-1.9×10−6), choline (2.3-2.9×10−5), and p-aminobenzoic acid (6.8-7.4×10−8).
6. The composition of claim 5 , wherein the electrolytes are present in concentrations of Na (3.1×10−2), Cl (2.3×10−2), Ca (5.2×10−3), K (6.1×10−3), Mg (8.2×10−5), PO4 (3.1×10−4), and HCO3 (3×10−3); ionic constituents are present in a concentration of SO4 (4.2×10−4), S (2.3×10−3), F (1.1×10−5), P (1.3×10−5), Br (2.3×10−6), Cd (1.8×10−8), Cu (9.4×10−7), I (7.1×10−8), Fe (9.8×10−6), Pb (1.2×10−7), Mn (1.1×10−6), Ni (4.2×10−7), and Zn (1.3×10−5); organic acids and carbohydrates are present in concentrations of lactic acid (1.4×10−2), pyruvic acid (1.8×10−4), butyric acid (2.4×10−6), acetic acid (1.3×10−4), hexanoic acid (9.0×10−7), propionic acid (3.5×10−6), isobutyric acid (8.0×10−7), isovaleric acid (1.1×10−6), and glucose (1.7×10−4); amino acids are present in concentrations of alanine (3.6×10−4), arginine (7.8×10−4), aspartic acid (3.4×10−4), citrulline (4.0×10−4), glutamic acid (3.7×10−4), glycine (3.9×10−4), histidine (5.2×10−4), isoleucine (1.7×10−4), leucine (2.1×10−4), lysine (1.5×10−4), ornithine (1.5×10−4), phenylalanine (1.3×10−4), threonine (4.5×10−4), tryptophan (5.5×10−5), tyrosine (1.7×10−4), and valine (2.5×10−4); the nitrogenous substances are present in concentrations of NH3 (5.2×10−3), urea (1.0×10−2), uric acid (5.9×10−5), creatinine (8.4×10−5), and creatine (1.5×10−5); the vitamins are present in concentrations of thiamine (5.0×10−3), riboflavin (2.0×10−3), niacin (4.1×10−1), pantothenic acid (1.3×10−1), pyridoxine (1.0×10−8), folic acid (1.6×10−8), ascorbic acid (1.0×10−5) and/or its oxidation product dehydroascorbic acid (1.1×10−5), inositol (1.6×10−6), choline (2.6×10−5), and p-aminobenzoic acid (7.1×10−8); and the composition is at a pH of about 5.3.
7. The composition of claim 2 , wherein the sebum formulation comprises 8-12% squalene, 23-27% wax esters, 30-35% triglycerides, 25-30% free fatty acids, 1-3% cholesterol esters, and 3-5% free cholesterol.
8. The composition of claim 2 , wherein the sebum formulation comprises 10% squalene, 25% wax esters, 33% triglycerides, 28% free fatty acids, 2% cholesterol esters, and 4% free cholesterol.
9. The composition of claim 7 , wherein the wax esters comprise palmityl palmitate and oleyl oleate; the triglycerides comprise tristearin and triolein; the free fatty acids comprise stearic, palmitic and oleic acid; the cholesterol esters comprise cholesteryl oleate; and the Vitamin E comprises (±)-α-tocopherol.
10. The composition of claim 8 , wherein the sebum formulation comprises:
11. An artificial sweat composition comprising:
12. A method of making the artificial sweat composition of claim 1 , comprising:
providing a volume of water of about 70-80% of a final desired liquid volume of the artificial sweat composition;
first adding the primary electrolytes and ionic constituents to the water to form a primary solution;
then adding the organic acids, amino acids, nitrogenous substances and vitamins to the primary solution.
13. A method of storing the composition of claim 2 , comprising placing it in a container under a nitrogen gas blanket at 4° C.
14. The method of claim 14 , further comprising storing the composition at a pH greater than 5.
15. A method of testing dissolution of an object in human sweat, comprising
exposing the object to the composition of claim 1 for a sufficient period of time for it to at least partially dissolve;
quantifying dissolution of the object in the composition.
16. The method of claim 14 , wherein the composition further comprises artificial sebum.
17. The method of claim 15 , wherein the artificial sweat and sebum are present in a mass ratio of at least 1% artificial sebum.
18. The method of claim 15 , wherein the artificial sebum is present in a layer present in the composition while exposing the object to the composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/137,391 US20080311613A1 (en) | 2007-06-14 | 2008-06-11 | Artificial skin surface film liquids |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93486107P | 2007-06-14 | 2007-06-14 | |
| US12/137,391 US20080311613A1 (en) | 2007-06-14 | 2008-06-11 | Artificial skin surface film liquids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20080311613A1 true US20080311613A1 (en) | 2008-12-18 |
Family
ID=40132698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/137,391 Abandoned US20080311613A1 (en) | 2007-06-14 | 2008-06-11 | Artificial skin surface film liquids |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US20080311613A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013151725A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Regenerative sera cells and mesenchymal stem cells |
| US8716024B2 (en) * | 2007-12-10 | 2014-05-06 | Bayer Healthcare Llc | Control solution for use in testing an electrochemical system |
| CN106117069A (en) * | 2016-06-17 | 2016-11-16 | 宜兴市前成生物有限公司 | A kind of method preparing L glutamate chelate potassium one water thing |
| WO2019160793A3 (en) * | 2018-02-13 | 2020-05-07 | Microban Products Company | Synthetic sweat composition, sweat odor kit, and method of use |
| CN111363471A (en) * | 2020-03-30 | 2020-07-03 | 东南大学 | A kind of artificial fingerprint liquid and its preparation method and application |
| CN114487080A (en) * | 2022-01-11 | 2022-05-13 | 厦门华厦学院 | Method and system for assessing health risk of heavy metal in farmland system |
| CN115605092A (en) * | 2020-02-28 | 2023-01-13 | 马可欣(Us) | Formulations and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5796016A (en) * | 1995-12-12 | 1998-08-18 | Erweka Gmbh | Dissolution tester |
| US6887859B2 (en) * | 2001-09-26 | 2005-05-03 | The Procter & Gamble Company | Topical compositions containing fluid-absorbent solids and adhesive fluids |
| US20050175646A1 (en) * | 2001-10-30 | 2005-08-11 | Philippe Catroux | Cosmetic composition that mimics sebum and the use thereof |
| US20060260421A1 (en) * | 2005-05-17 | 2006-11-23 | Jasco Corporation | Dissolution tester |
-
2008
- 2008-06-11 US US12/137,391 patent/US20080311613A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5796016A (en) * | 1995-12-12 | 1998-08-18 | Erweka Gmbh | Dissolution tester |
| US6887859B2 (en) * | 2001-09-26 | 2005-05-03 | The Procter & Gamble Company | Topical compositions containing fluid-absorbent solids and adhesive fluids |
| US20050175646A1 (en) * | 2001-10-30 | 2005-08-11 | Philippe Catroux | Cosmetic composition that mimics sebum and the use thereof |
| US20060260421A1 (en) * | 2005-05-17 | 2006-11-23 | Jasco Corporation | Dissolution tester |
Non-Patent Citations (3)
| Title |
|---|
| Boman et al. (Contact Dermatitis, 9 2 (1983), pp. 159-160) * |
| Cage and Dobson (Journal of Clinical Investigation, Vol. 44, No. 7, 1965, pages 1270-1276). * |
| Hostynek (Arch Dermatol Res (2002) 294 :249-267) * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8716024B2 (en) * | 2007-12-10 | 2014-05-06 | Bayer Healthcare Llc | Control solution for use in testing an electrochemical system |
| US8871517B2 (en) | 2007-12-10 | 2014-10-28 | Bayer Healthcare Llc | Method of using a control solution and preparing for testing using the same |
| US9933385B2 (en) | 2007-12-10 | 2018-04-03 | Ascensia Diabetes Care Holdings Ag | Method of using an electrochemical test sensor |
| US10690614B2 (en) | 2007-12-10 | 2020-06-23 | Ascensia Diabetes Care Holdings Ag | Method of using an electrochemical test sensor |
| WO2013151725A1 (en) | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Regenerative sera cells and mesenchymal stem cells |
| CN106117069A (en) * | 2016-06-17 | 2016-11-16 | 宜兴市前成生物有限公司 | A kind of method preparing L glutamate chelate potassium one water thing |
| WO2019160793A3 (en) * | 2018-02-13 | 2020-05-07 | Microban Products Company | Synthetic sweat composition, sweat odor kit, and method of use |
| CN111683647A (en) * | 2018-02-13 | 2020-09-18 | 美可帮产品公司 | Synthetic sweat composition, sweat odor kit and method of use |
| CN115605092A (en) * | 2020-02-28 | 2023-01-13 | 马可欣(Us) | Formulations and uses thereof |
| CN111363471A (en) * | 2020-03-30 | 2020-07-03 | 东南大学 | A kind of artificial fingerprint liquid and its preparation method and application |
| CN114487080A (en) * | 2022-01-11 | 2022-05-13 | 厦门华厦学院 | Method and system for assessing health risk of heavy metal in farmland system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080311613A1 (en) | Artificial skin surface film liquids | |
| McKenna | Substrate competition studies demonstrate oxidative metabolism of glucose, glutamate, glutamine, lactate and 3-hydroxybutyrate in cortical astrocytes from rat brain | |
| Stott | The influence of diet on the δ13C of shell carbon in the pulmonate snail Helix aspersa | |
| Harvey et al. | Formulation and stability of a novel artificial human sweat under conditions of storage and use | |
| Benjamin et al. | Metabolism of amino acids and ammonia in rat brain cortex slices in vitro: a possible role of ammonia in brain function | |
| Alfthan et al. | Selenium metabolism and platelet glutathione peroxidase activity in healthy Finnish men: effects of selenium yeast, selenite, and selenate | |
| Quilliot et al. | Evidence that diabetes mellitus favors impaired metabolism of zinc, copper, and selenium in chronic pancreatitis | |
| Elmas et al. | The prooxidant effect of sodium metabisulfite in rat liver and kidney | |
| Paul et al. | Effect of carnitine on branched-chain amino acid oxidation by liver and skeletal muscle. | |
| EP3421999B1 (en) | Customized quality controls for analytical assays | |
| Lever et al. | Short and long-term variation of plasma glycine betaine concentrations in humans | |
| Paul et al. | Assessment of effect of starvation, glucose, fatty acids and hormones on α-decarboxylation of leucine in skeletal muscle of rat | |
| Paik et al. | Serum extracellular superoxide dismutase activity as an indicator of zinc status in humans | |
| Shibata et al. | Changes in urine composition, bladder epithelial morphology, and DNA synthesis in male F344 rats in response to ingestion of bladder tumor promoters | |
| Mylroie et al. | Increased susceptibility to lead toxicity in rats fed semipurified diets | |
| Rafael et al. | The effect of essential fatty acid deficiency on basal respiration and function of liver mitochondria in rats | |
| Ostrenko et al. | Effect of lithium ascorbate on the biochemical parameters of sows | |
| Lawal et al. | Assessment of levels of copper, cadmium and lead in secretion of mammary gland of cows grazed on open fields | |
| JPH0840B2 (en) | Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agent | |
| Doris | Digoxin-like immunoreactive factor in rat plasma: effect of sodium and calcium intake | |
| Sunde et al. | Regulation of expression of glutathione peroxidase by selenium | |
| Uthus et al. | Dietary nickel and folic acid interact to affect folate and methionine metabolism in the rat | |
| Arnaud et al. | Selenium status in an iodine deficient population of the West Ivory Coast | |
| Baker et al. | A practical assay of lipoate in biologic fluids and liver in health and disease | |
| Padovese et al. | Biological importance of γ-glutamyl-S-methylcysteine of kidney bean (Phaseolus vulgaris L.) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STEFANIAK, ALEKSANDR B.;HARVEY, CHRISTOPHER J.;REEL/FRAME:021307/0159;SIGNING DATES FROM 20080716 TO 20080717 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |